Giuseppe Remuzzi

List of Publications by Year in descending order

1,115 papers	180,827 citations	56 173 h-index	43 385 g-index
1431 all docs	1431 docs citations	1431 times ranked	134088 citing authors

#	Article	IF	Citations
1	Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2095-2128.	11.9	11,297
2	Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2197-2223.	11.9	7,201
3	Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. New England Journal of Medicine, 2001, 345, 861-869.	29.6	6,691
4	Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990â€“2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2163-2196.	11.9	6,546
5	Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1459-1544.	11.9	5,141
6	Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 743-800.	11.9	5,124
7	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1659-1724.	11.9	4,401
8	Global, regional, and national age-sex specific mortality for 264 causes of death, 1980â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1151-1210.	11.9	3,733
9	Global, regional, and national burden of chronic kidney disease, 1990â€“2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet, The, 2020, 395, 709-733.	11.9	3,341
10	COVID-19 and Italy: what next?. Lancet, The, 2020, 395, 1225-1228.	11.9	2,473
11	Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2015, 386, 2287-2323.	11.9	2,274
12	A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease. New England Journal of Medicine, 2009, 361, 2019-2032.	29.6	2,136
13	Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis. New England Journal of Medicine, 2009, 360, 1395-1407.	29.6	1,806
14	von Willebrand Factorâ€“Cleaving Protease in Thrombotic Thrombocytopenic Purpura and the Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 1998, 339, 1578-1584.	29.6	1,730
15	Global, regional, and national disability-adjusted life-years (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1603-1658.	11.9	1,680
16	Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1260-1344.	11.9	1,647
17	Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990â€“2013: quantifying the epidemiological transition. Lancet, The, 2015, 386, 2145-2191.	11.9	1,594
18	Terminal Complement Inhibitor Eculizumab in Atypical Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 2013, 368, 2169-2181.	29.6	1,307

#	Article	IF	Citations
19	Atypical Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 2009, 361, 1676-1687.	29.6	1,168
20	The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney International, 2011, 80, 1258-1270.	5.3	1,154
21	Pathophysiology of Progressive Nephropathies. New England Journal of Medicine, 1998, 339, 1448-1456.	29.6	1,145
22	Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet, The, 2012, 380, 2129-2143.	11.9	1,045
23	Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2004, 351, 1941-1951.	29.6	956
24	Angiotensin-Converting Enzyme Inhibitors and Progression of Nondiabetic Renal Disease. Annals of Internal Medicine, 2001, 135, 73.	10.0	942
25	Panethnic Differences in Blood Pressure in Europe: A Systematic Review and Meta-Analysis. PLoS ONE, 2016, 11, e0147601.	2.5	942
26	Bardoxolone Methyl in Type 2 Diabetes and Stage 4 Chronic Kidney Disease. New England Journal of Medicine, 2013, 369, 2492-2503.	29.6	871
27	Relative Role of Genetic Complement Abnormalities in Sporadic and Familial aHUS and Their Impact on Clinical Phenotype. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1844-1859.	4.3	851
28	Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney International, 2004, 65, 2309-2320.	5.3	848
29	Delayed graft function in kidney transplantation. Lancet, The, 2004, 364, 1814-1827.	11.9	848
30	International Society of Nephrology's 0by25 initiative for acute kidney injury (zero preventable deaths) Tj ETQq0 0 0 rgBT /Overlock 10 T	11.9	825
31	Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet, The, 1999, 354, 359-364.	11.9	809
32	Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990â€“2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet, The, 2014, 384, 1005-1070.	11.9	801
33	Global, regional, and national levels of maternal mortality, 1990â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1775-1812.	11.9	782
34	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet, The, 2017, 390, 1888-1917.	11.9	708
35	Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy. Circulation, 2004, 110, 921-927.	6.2	688
36	Genetics of HUS: the impact of MCP, CFH, and IF mutations on clinical presentation, response to treatment, and outcome. Blood, 2006, 108, 1267-1279.	1.4	664

#	Article	IF	Citations
37	Overview of Complement Activation and Regulation. Seminars in Nephrology, 2013, 33, 479-492.	1.5	648
38	Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney International, 2011, 79, 1331-1340.	5.3	630
39	Deamino-8-D-Arginine Vasopressin Shortens the Bleeding Time in Uremia. New England Journal of Medicine, 1983, 308, 8-12.	29.6	625
40	Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet, The, 2010, 376, 1543-1551.	11.9	620
41	Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Molecular Medicine, 2010, 2, 247-257.	6.8	612
42	Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980â€“2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1725-1774.	11.9	604
43	Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet, The, 2005, 365, 939-946.	11.9	598
44	Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970â€“2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet, The, 2017, 390, 1084-1150.	11.9	594
45	Understanding the nature of renal disease progression. Kidney International, 1997, 51, 2-15.	5.3	574
46	Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy. JAMA - Journal of the American Medical Association, 2015, 314, 884.	6.9	548
47	Nephropathy in Patients with Type 2 Diabetes. New England Journal of Medicine, 2002, 346, 1145-1151.	29.6	539
48	Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet, The, 1998, 352, 1252-1256.	11.9	524
49	Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes. Journal of Clinical Investigation, 2006, 116, 288-296.	6.5	516
50	Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990â€“2015: a novel analysis from the Global Burden of Disease Study 2015. Lancet, The, 2017, 390, 231-266.	11.9	511
51	Global and National Burden of Diseases and Injuries Among Children and Adolescents Between 1990 and 2013. JAMA Pediatrics, 2016, 170, 267.	6.1	505
52	Thrombomodulin Mutations in Atypical Hemolyticâ€“Uremic Syndrome. New England Journal of Medicine, 2009, 361, 345-357.	29.6	502
53	Progression, remission, regression of chronic renal diseases. Lancet, The, 2001, 357, 1601-1608.	11.9	495
54	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet, The, 2021, 397, 1625-1636.	11.9	495

#	Article	IF	Citations
55	Immunity, endothelial injury and complement-induced coagulopathy in COVID-19. Nature Reviews Nephrology, 2021, 17, 46-64.	9.3	477
56	Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980â€“2015: the Global Burden of Disease Study 2015. Lancet HIV,the, 2016, 3, e361-e387.	4.5	469
57	Long-Term Outcome of Renal Transplantation from Older Donors. New England Journal of Medicine, 2006, 354, 343-352.	29.6	456
58	Nitric Oxide Synthesis by Cultured Endothelial Cells Is Modulated by Flow Conditions. Circulation Research, 1995, 76, 536-543.	6.5	444
59	Disruption of the Ang II type 1 receptor promotes longevity in mice. Journal of Clinical Investigation, 2009, 119, 524-530.	6.5	441
60	Erythropoietic Response and Outcomes in Kidney Disease and Type 2 Diabetes. New England Journal of Medicine, 2010, 363, 1146-1155.	29.6	440
61	Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. Lancet, The, 2016, 388, 1813-1850.	11.9	433
62	Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients: A global perspective. Kidney International, 2006, 69, 2057-2063.	5.3	423
63	Thrombotic microangiopathy, hemolytic uremic syndrome, and thrombotic thrombocytopenic purpura. Kidney International, 2001, 60, 831-846.	5.3	407
64	Pretransplant Infusion of Mesenchymal Stem Cells Prolongs the Survival of a Semiallogeneic Heart Transplant through the Generation of Regulatory T Cells. Journal of Immunology, 2008, 181, 3933-3946.	0.8	407
65	Platelet Dysfunction in Renal Failure. Seminars in Thrombosis and Hemostasis, 2004, 30, 579-589.	2.7	401
66	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2017, 318, 432.	6.9	395
67	The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease. Kidney International, 2005, 68, S57-S65.	5.3	388
68	Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. The Lancet Global Health, 2016, 4, e307-e319.	6.2	385
69	Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. Kidney International, 1998, 53, 1209-1216.	5.3	382
70	Leukocyte-endothelial interaction is augmented by high glucose concentrations and hyperglycemia in a NF-kB-dependent fashion.. Journal of Clinical Investigation, 1998, 101, 1905-1915.	6.5	382
71	Prognosis of Untreated Patients with Idiopathic Membranous Nephropathy. New England Journal of Medicine, 1993, 329, 85-89.	29.6	381
72	Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kB activation. Kidney International, 1998, 53, 1608-1615.	5.3	374

#	Article	IF	Citations
73	Human Bone Marrow Mesenchymal Stem Cells Accelerate Recovery of Acute Renal Injury and Prolong Survival in Mice. Stem Cells, 2008, 26, 2075-2082.	3.5	353
74	Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney International, 2015, 87, 1061-1073.	5.3	352
75	Sirtuin 3â€“dependent mitochondrial dynamic improvements protect against acute kidney injury. Journal of Clinical Investigation, 2015, 125, 715-726.	6.5	349
76	Is glomerulosclerosis a consequence of altered glomerular permeability to macromolecules?. Kidney International, 1990, 38, 384-394.	5.3	347
77	Infant wellbeing at 2 years of age in the Growth Restriction Intervention Trial (GRIT): multicentred randomised controlled trial. Lancet, The, 2004, 364, 513-520.	11.9	342
78	STEC-HUS, atypical HUS and TTP are all diseases of complement activation. Nature Reviews Nephrology, 2012, 8, 622-633.	9.3	339
79	Early Experience with Dual Kidney Transplantation in Adults using Expanded Donor Criteria. Journal of the American Society of Nephrology: JASN, 1999, 10, 2591-2598.	0.5	339
80	Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease. Kidney International, 2001, 60, 1131-1140.	5.3	336
81	Effect of Low-Dose Aspirin on Fetal and Maternal Generation of Thromboxane by Platelets in Women at Risk for Ppregnancy-Induced Hypertension. New England Journal of Medicine, 1989, 321, 357-362.	29.6	332
82	Rituximab for idiopathic membranous nephropathy. Lancet, The, 2002, 360, 923-924.	11.9	321
83	Child and Adolescent Health From 1990 to 2015. JAMA Pediatrics, 2017, 171, 573.	6.1	321
84	MicroRNAs in kidney physiology and disease. Nature Reviews Nephrology, 2015, 11, 23-33.	9.3	319
85	Recognition and management of acute kidney injury in the International Society of Nephrology 0by25 Global Snapshot: a multinational cross-sectional study. Lancet, The, 2016, 387, 2017-2025.	11.9	317
86	Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. Journal of Clinical Investigation, 2003, 111, 1181-1190.	6.5	317
87	Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype. Journal of the American Society of Nephrology: JASN, 2013, 24, 475-486.	0.5	313
88	URAEMIC BLEEDING: ROLE OF ANAEMIA AND BENEFICIAL EFFECT OF RED CELL TRANSFUSIONS. Lancet, The, 1982, 320, 1013-1015.	11.9	308
89	Familial haemolytic uraemic syndrome and an MCP mutation. Lancet, The, 2003, 362, 1542-1547.	11.9	307
90	Transfer of Growth Factor Receptor mRNA Via Exosomes Unravels the Regenerative Effect of Mesenchymal Stem Cells. Stem Cells and Development, 2013, 22, 772-780.	2.1	305

#	Article	IF	Citations
91	Chronic renal diseases as a public health problem: Epidemiology, social, and economic implications. Kidney International, 2005, 68, S7-S10.	5.3	301
92	Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood, 2014, 124, 1715-1726.	1.4	298
93	Anti-Phospholipase A2 Receptor Antibody Titer Predicts Post-Rituximab Outcome of Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2015, 26, 2545-2558.	0.5	297
94	Complement factor H mutations and gene polymorphisms in haemolytic uraemic syndrome: the C-257T, the A2089G and the G2881T polymorphisms are strongly associated with the disease. Human Molecular Genetics, 2003, 12, 3385-3395.	3.0	291
95	Efficiency of curative and prophylactic treatment with rituximab in ADAMTS13-deficient thrombotic thrombocytopenic purpura: a study of 11 cases. Blood, 2005, 106, 1932-1937.	1.4	291
96	The case of complement activation in COVID-19 multiorgan impact. Kidney International, 2020, 98, 314-322.	5.3	287
97	Sodium Intake, ACE Inhibition, and Progression to ESRD. Journal of the American Society of Nephrology: JASN, 2012, 23, 165-173.	0.5	281
98	ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases. Blood, 2005, 106, 1262-1267.	1.4	278
99	Podocytopathies. Nature Reviews Disease Primers, 2020, 6, 68.	18.4	278
100	HqMOLYTIC-URqMIC SYNDROME: DEFICIENCY OF PLASMA FACTOR(S) REGULATING PROSTACYCLIN ACTIVITY?. Lancet, The, 1978, 312, 871-872.	11.9	275
101	Autologous Mesenchymal Stromal Cells and Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 412-422.	4.3	274
102	Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. Diabetes Care, 2012, 35, 2061-2068.	9.0	266
103	The Molecular Basis of Familial Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2001, 12, 297-307.	0.5	265
104	Strategies for Making More Organs Available for Transplantation. New England Journal of Medicine, 2000, 343, 404-410.	29.6	263
105	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2012, 23, 1416-1425.	0.5	263
106	Mechanisms of Disease: pre-eclampsia. Nature Clinical Practice Nephrology, 2005, 1, 98-114.	0.9	262
107	The RAAS in the pathogenesis and treatment of diabetic nephropathy. Nature Reviews Nephrology, 2010, 6, 319-330.	9.3	259
108	Retarding progression of chronic renal disease: The neglected issue of residual proteinuria. Kidney International, 2003, 63, 2254-2261.	5.3	245

#	Article	IF	Citations
109	Factor H family proteins: on complement, microbes and human diseases. Biochemical Society Transactions, 2002, 30, 971-978.	3.4	244
110	Novel methods for disinfection of prion-contaminated medical devices. Lancet, The, 2004, 364, 521-526.	11.9	242
111	A classification of hemolytic uremic syndrome and thrombotic thrombocytopenic purpura and related disorders. Kidney International, 2006, 70, 423-431.	5.3	241
112	C3 glomerulopathy â€" understanding a rare complement-driven renal disease. Nature Reviews Nephrology, 2019, 15, 129-143.	9.3	241
113	Endothelin antagonists. Lancet, The, 1999, 353, 133-138.	11.9	240
114	Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney International, 2005, 68, 206-216.	5.3	239
115	Chronic Renal Diseases: Renoprotective Benefits of Reninâ€"Angiotensin System Inhibition. Annals of Internal Medicine, 2002, 136, 604.	10.0	238
116	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes and Endocrinology,the, 2019, 7, 128-139.	11.1	237
117	HUS and TTP: Variable expression of a single entity. Kidney International, 1987, 32, 292-308.	5.3	236
118	Reduced umbilical and placental vascular prostacyclin in severe pre-eclampsia. Prostaglandins, 1980, 20, 105-110.	1.1	235
119	Proximal tubular cell synthesis and secretion of endothelin-1 on challenge with albumin and other proteins. American Journal of Kidney Diseases, 1995, 26, 934-941.	1.9	233
120	Spectrum of Steroid-Resistant and Congenital Nephrotic Syndrome in Children. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 592-600.	4.3	233
121	Mechanisms and Treatment of CKD. Journal of the American Society of Nephrology: JASN, 2012, 23, 1917-1928.	0.5	231
122	Angiotensin converting enzyme inhibition ameliorates glomerular filtration of macromolecules and water and lessens glomerular injury in the rat.. Journal of Clinical Investigation, 1990, 85, 541-549.	6.5	231
123	A phase 1, single-dose study of fresolimumab, an anti-TGF-Î² antibody, in treatment-resistant primary focal segmental glomerulosclerosis. Kidney International, 2011, 79, 1236-1243.	5.3	230
124	The Endothelin Antagonist Atrasentan Lowers Residual Albuminuria in Patients with Type 2 Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2014, 25, 1083-1093.	0.5	229
125	MYO1EMutations and Childhood Familial Focal Segmental Glomerulosclerosis. New England Journal of Medicine, 2011, 365, 295-306.	29.6	228
126	Cross sectional longitudinal study of spot morning urine protein:creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rate, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ: British Medical Journal, 1998, 316, 504-509.	5.6	224

#	Article	IF	Citations
127	Alternative Pathway Activation of Complement by Shiga Toxin Promotes Exuberant C3a Formation That Triggers Microvascular Thrombosis. Journal of Immunology, 2011, 187, 172-180.	0.8	223
128	Effect of longacting somatostatin analogue on kidney and cyst growth in autosomal dominant polycystic kidney disease (ALADIN): a randomised, placebo-controlled, multicentre trial. Lancet, The, 2013, 382, 1485-1495.	11.9	222
129	Conjugated Estrogens for the Management of Bleeding Associated with Renal Failure. New England Journal of Medicine, 1986, 315, 731-735.	29.6	217
130	A specific endothelin subtype A receptor antagonist protects against injury in renal disease progression. Kidney International, 1993, 44, 440-444.	5.3	216
131	Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes and Endocrinology,the, 2019, 7, 115-127.	11.1	216
132	Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney International, 2002, 62, 1060-1067.	5.3	215
133	Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD. Journal of the American Society of Nephrology: JASN, 2015, 26, 1732-1746.	0.5	213
134	Rituximab in Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2003, 14, 1851-1857.	0.5	209
135	Outcome of Renal Transplantation in Patients with Nonâ€“Shiga Toxinâ€“Associated Hemolytic Uremic Syndrome: Prognostic Significance of Genetic Background. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 88-99.	4.3	206
136	Rituximab in Steroid-Dependent or Frequently Relapsing Idiopathic Nephrotic Syndrome. Journal of the American Society of Nephrology: JASN, 2014, 25, 850-863.	0.5	206
137	Enhanced nitric oxide synthesis in uremia: Implications for platelet dysfunction and dialysis hypotension. Kidney International, 1993, 44, 445-450.	5.3	205
138	Global Cardiovascular and Renal Outcomes of Reduced GFR. Journal of the American Society of Nephrology: JASN, 2017, 28, 2167-2179.	0.5	205
139	Estimated GFR: time for a critical appraisal. Nature Reviews Nephrology, 2019, 15, 177-190.	9.3	203
140	von Willebrand factor cleaving protease (ADAMTS13) is deficient in recurrent and familial thrombotic thrombocytopenic purpura and hemolytic uremic syndrome. Blood, 2002, 100, 778-785.	1.4	200
141	Rare inherited kidney diseases: challenges, opportunities, and perspectives. Lancet, The, 2014, 383, 1844-1859.	11.9	200
142	Early-Childhood Membranous Nephropathy Due to Cationic Bovine Serum Albumin. New England Journal of Medicine, 2011, 364, 2101-2110.	29.6	198
143	Uremic Bleeding: Closing the Circle After 30 Years of Controversies?. Blood, 1999, 94, 2569-2574.	1.4	194
144	BLEEDING IN RENAL FAILURE. Lancet, The, 1988, 331, 1205-1208.	11.9	193

#	Article	IF	Citations
145	Thrombotic Microangiopathy After Kidney Transplantation. American Journal of Transplantation, 2010, 10, 1517-1523.	4.7	193
146	Fluid shear stress modulates surface expression of adhesion molecules by endothelial cells. Blood, 1995, 85, 1696-1703.	1.4	191
147	Phosphate May Promote CKD Progression and Attenuate Renoprotective Effect of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2011, 22, 1923-1930.	0.5	190
148	Renal Vascular and Thrombotic Effects of Cyclosporine. American Journal of Kidney Diseases, 1989, 13, 261-272.	1.9	189
149	Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney International, 1993, 43, 706-711.	5.3	189
150	Nonviral Gene Delivery to the Rat Kidney with Polyethylenimine. Human Gene Therapy, 1997, 8, 1243-1251.	2.9	188
151	Renal replacement therapy for autosomal dominant polycystic kidney disease (ADPKD) in Europe: prevalence and survival--an analysis of data from the ERA-EDTA Registry. Nephrology Dialysis Transplantation, 2014, 29, iv15-iv25.	0.7	186
152	Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus.. Journal of Clinical Investigation, 1985, 76, 1011-1018.	6.5	186
153	Performance of Different Prediction Equations for Estimating Renal Function in Kidney Transplantation. American Journal of Transplantation, 2004, 4, 1826-1835.	4.7	184
154	Time to abandon microalbuminuria?. Kidney International, 2006, 70, 1214-1222.	5.3	184
155	The hemolytic uremic syndrome. Kidney International, 1995, 48, 2-19.	5.3	183
156	Add-On Antiâ€“TGF-Î² Antibody to ACE Inhibitor Arrests Progressive Diabetic Nephropathy in the Rat. Journal of the American Society of Nephrology: JASN, 2003, 14, 1816-1824.	0.5	177
157	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 1: How to measure glomerular filtration rate with iohexol?. CKJ: Clinical Kidney Journal, 2016, 9, 682-699.	2.7	177
158	Risk Scores for Predicting Outcomes in Patients with Type 2 Diabetes and Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 761-767.	4.3	176
159	Renal Progenitor Cells Contribute to Hyperplastic Lesions of Podocytopathies and Crescentic Glomerulonephritis. Journal of the American Society of Nephrology: JASN, 2009, 20, 2593-2603.	0.5	176
160	Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury. American Journal of Kidney Diseases, 2000, 35, 1155-1165.	1.9	175
161	Renal progenitors: an evolutionary conserved strategy for kidney regeneration. Nature Reviews Nephrology, 2013, 9, 137-146.	9.3	174
162	Recellularization of Well-Preserved Acellular Kidney Scaffold Using Embryonic Stem Cells. Tissue Engineering - Part A, 2014, 20, 1486-1498.	3.2	171

#	Article	IF	Citations
163	Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney International, 2003, 63, 1094-1103.	5.3	168
164	Maintenance Dialysis throughout the World in Years 1990 and 2010. Journal of the American Society of Nephrology: JASN, 2015, 26, 2621-2633.	0.5	163
165	Life-Sparing Effect of Human Cord Blood-Mesenchymal Stem Cells in Experimental Acute Kidney Injury. Stem Cells, 2010, 28, 513-522.	3.5	161
166	Podocyteâ€“actin dynamics in health and disease. Nature Reviews Nephrology, 2016, 12, 692-710.	9.3	161
167	The interactive Factor H-atypical hemolytic uremic syndrome mutation database and website: update and integration of membrane cofactor protein and Factor I mutations with structural models. Human Mutation, 2007, 28, 222-234.	2.7	160
168	In Vivo Maturation of Functional Renal Organoids Formed from Embryonic Cell Suspensions. Journal of the American Society of Nephrology: JASN, 2012, 23, 1857-1868.	0.5	160
169	Tubulo-interstitial lesions mediate renal damage in adriamycin glomerulopathy. Kidney International, 1986, 30, 488-496.	5.3	158
170	Sirolimus Therapy to Halt the Progression of ADPKD. Journal of the American Society of Nephrology: JASN, 2010, 21, 1031-1040.	0.5	158
171	Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?. CKJ: Clinical Kidney Journal, 2016, 9, 700-704.	2.7	158
172	How To Fully Protect the Kidney in a Severe Model of Progressive Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, 2898-2908.	0.5	156
173	Mycophenolate mofetil versus azathioprine for prevention of acute rejection in renal transplantation (MYSS): a randomised trial. Lancet, The, 2004, 364, 503-512.	11.9	156
174	Titrating Rituximab to Circulating B Cells to Optimize Lymphocytolytic Therapy in Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 932-937.	4.3	156
175	Localization of Mesenchymal Stromal Cells Dictates Their Immune or Proinflammatory Effects in Kidney Transplantation. American Journal of Transplantation, 2012, 12, 2373-2383.	4.7	155
176	Long-Term Outcome of Steroid-Resistant Nephrotic Syndrome in Children. Journal of the American Society of Nephrology: JASN, 2017, 28, 3055-3065.	0.5	155
177	Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet, The, 2002, 359, 1671-1672.	11.9	154
178	Reduced Platelet Thromboxane Formation in Uremia. EVIDENCE FOR A FUNCTIONAL CYCLOOXYGENASE DEFECT. Journal of Clinical Investigation, 1983, 71, 762-768.	6.5	153
179	Renal endothelin gene expression is increased in remnant kidney and correlates with disease progression. Kidney International, 1993, 43, 354-358.	5.3	153
180	In Response to Protein Load Podocytes Reorganize Cytoskeleton and Modulate Endothelin-1 Gene. American Journal of Pathology, 2005, 166, 1309-1320.	4.0	152

#	Article	IF	Citations
181	Hemolytic Uremic Syndrome in Pregnancy and Postpartum. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1237-1247.	4.3	152
182	DAILY RENAL HYPOPERFUSION INDUCED BY CYCLOSPORINE IN PATIENTS WITH RENAL TRANSPLANTATION. Transplantation, 1992, 54, 56-60.	1.0	151
183	Mesenchymal stromal cells and kidney transplantation: pretransplant infusion protects from graft dysfunction while fostering immunoregulation. Transplant International, 2013, 26, 867-878.	1.7	151
184	Increased glomerular thromboxane synthesis as a possible cause of proteinuria in experimental nephrosis.. Journal of Clinical Investigation, 1985, 75, 94-101.	6.5	149
185	Protein traffic activates NF-kB gene signaling and promotes MCP-1â€“dependent interstitial inflammation. American Journal of Kidney Diseases, 2000, 36, 1226-1241.	1.9	146
186	EPSTEIN-BARR VIRUS-NEGATIVE LYMPHOPROLIFERATIVE DISORDERS IN LONG-TERM SURVIVORS AFTER HEART, KIDNEY, AND LIVER TRANSPLANT1. Transplantation, 2000, 69, 827-833.	1.0	146
187	The rate of progression of renal disease may not be slower in women compared with men: a patient-level meta-analysis. Nephrology Dialysis Transplantation, 2003, 18, 2047-2053.	0.7	145
188	A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes. Diabetes, 2018, 67, 1414-1427.	0.9	142
189	Eculizumab in a Patient with Dense-Deposit Disease. New England Journal of Medicine, 2012, 366, 1161-1163.	29.6	141
190	<scp>l</scp> -Arginine Depletion in Preeclampsia Orients Nitric Oxide Synthase Toward Oxidant Species. Hypertension, 2004, 43, 614-622.	4.9	140
191	Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney International, 1997, 52, 171-181.	5.3	138
192	Transforming Growth Factor-Î²1 Is Up-Regulated by Podocytes in Response to Excess Intraglomerular Passage of Proteins. American Journal of Pathology, 2002, 161, 2179-2193.	4.0	138
193	Characterization of mutations in complement factor I (CFI) associated with hemolytic uremic syndrome. Molecular Immunology, 2008, 45, 95-105.	2.4	138
194	Pathophysiologic Implications of Reduced Podocyte Number in a Rat Model of Progressive Glomerular Injury. American Journal of Pathology, 2006, 168, 42-54.	4.0	137
195	Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3 Glomerulopathy: Core Curriculum 2015. American Journal of Kidney Diseases, 2015, 66, 359-375.	1.9	137
196	The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney International, 2013, 84, 164-173.	5.3	136
197	Outrageous prices of orphan drugs: a call for collaboration. Lancet, The, 2018, 392, 791-794.	11.9	136
198	THYMIC RECOGNITION OF CLASS II MAJOR HISTOCOMPATIBILITY COMPLEX ALLOPEPTIDES INDUCES DONOR-SPECIFIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1993, 56, 461-465.	1.0	135

#	Article	IF	Citations
199	Mycophenolate mofetil limits renal damage and prolongs life in murine lupus autoimmune disease. Kidney International, 1997, 51, 1583-1589.	5.3	134
200	Mesenchymal stromal cells in renal transplantation: opportunities and challenges. Nature Reviews Nephrology, 2016, 12, 241-253.	9.3	134
201	Complement gene variants determine the risk of immunoglobulin-associated MPGN and C3 glomerulopathy and predict long-term renal outcome. Molecular Immunology, 2016, 71, 131-142.	2.4	134
202	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. JAMA - Journal of the American Medical Association, 2022, 327, 1888.	6.9	134
203	Sex related differences in glomerular ultrafiltration and proteinuria in Munich-Wistar rats. Kidney International, 1988, 34, 481-486.	5.3	133
204	Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy. Journal of Immunology, 2018, 200, 2464-2478.	0.8	133
205	Kidney graft survival in rats without immunosuppressants after intrathymic glomerular transplantation. Lancet, The, 1991, 337, 750-752.	11.9	132
206	Cellular responses to protein overload: key event in renal disease progression. Current Opinion in Nephrology and Hypertension, 2004, 13, 31-37.	2.0	132
207	Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. Journal of Hypertension, 2007, 25, 1921-1926.	0.5	132
208	New therapeutics that antagonize endothelin: promises and frustrations. Nature Reviews Drug Discovery, 2002, 1, 986-1001.	60.2	131
209	Treatment of Bleeding in Dialysis Patients. Seminars in Dialysis, 2009, 22, 279-286.	1.3	131
210	A developmental approach to the prevention of hypertension and kidney disease: a report from the Low Birth Weight and Nephron Number Working Group. Lancet, The, 2017, 390, 424-428.	11.9	131
211	Safety of Rituximab Compared with Steroids and Cyclophosphamide for Idiopathic Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2017, 28, 2729-2737.	0.5	131
212	Lymphomas occurring late after solid-organ transplantation. Transplantation, 2002, 74, 1095-1102.	1.0	130
213	Human mesenchymal stromal cells transplanted into mice stimulate renal tubular cells and enhance mitochondrial function. Nature Communications, 2017, 8, 983.	12.8	130
214	Mycophenolate Mofetil for the Treatment of Takayasu Arteritis: Report of Three Cases. Annals of Internal Medicine, 1999, 130, 422.	10.0	129
215	Plasma infusion for hemolytic-uremic syndrome in children: Results of a multicenter controlled trial. Journal of Pediatrics, 1988, 112, 284-290.	2.2	128
216	Bone Marrowâ€“Derived Mesenchymal Stem Cells Improve Islet Graft Function in Diabetic Rats. Transplantation Proceedings, 2009, 41, 1797-1800.	0.6	128

#	Article	IF	Citations
217	Reducing Polycystic Liver Volume in ADPKD. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 783-789.	4.3	128
218	Kidney regeneration. Lancet, The, 2010, 375, 1310-1317.	11.9	128
219	Angiotensin converting enzyme inhibition improves glomerular size-selectivity in IgA nephropathy. Kidney International, 1991, 39, 1267-1273.	5.3	127
220	Inhibition of the chemokine receptor CXCR2 prevents kidney graft function deterioration due to ischemia/reperfusion. Kidney International, 2005, 67, 1753-1761.	5.3	126
221	Mutations in FN1 cause glomerulopathy with fibronectin deposits. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 2538-2543.	7.4	126
222	Proteinuria should be used as a surrogate in CKD. Nature Reviews Nephrology, 2012, 8, 301-306.	9.3	126
223	SGLT2 inhibitor dapagliflozin limits podocyte damage in proteinuric nondiabetic nephropathy. Journal of Clinical Investigation, 2018, 3, .	6.5	126
224	MECHANISMS OF ACQUIRED THYMIC UNRESPONSIVENESS TO RENAL ALLOGRAFTS. Transplantation, 1994, 58, 125-132.	1.0	125
225	Multipotent Mesenchymal Stromal Cell Therapy and Risk of Malignancies. Stem Cell Reviews and Reports, 2013, 9, 65-79.	5.5	125
226	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. Blood, 1997, 90, 1558-1564.	1.4	124
227	Kidney Injury Molecule 1: In Search of Biomarkers of Chronic Tubulointerstitial Damage and Disease Progression. American Journal of Kidney Diseases, 2009, 53, 1-4.	1.9	123
228	ACE Inhibition Is Renoprotective among Obese Patients with Proteinuria. Journal of the American Society of Nephrology: JASN, 2011, 22, 1122-1128.	0.5	123
229	Endothelial injury and thrombotic microangiopathy in COVID-19: Treatment with the lectin-pathway inhibitor narsoplimab. Immunobiology, 2020, 225, 152001.	1.9	123
230	Blocking Angiotensin II Synthesis/Activity Preserves Glomerular Nephrin in Rats with Severe Nephrosis. Journal of the American Society of Nephrology: JASN, 2001, 12, 941-948.	0.5	123
231	Treatment of membranous nephropathy: time for a paradigm shift. Nature Reviews Nephrology, 2017, 13, 563-579.	9.3	122
232	Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 181-190.	11.1	121
233	Role of Insulin and Atrial Natriuretic Peptide in Sodium Retention in Insulin-Treated IDDM Patients During Isotonic Volume Expansion. Diabetes, 1990, 39, 289-298.	0.9	119
234	Monogenic diseases that can be cured by liver transplantation. Journal of Hepatology, 2013, 59, 595-612.	3.8	119

#	Article	IF	Citations
235	Hemolytic Uremic Syndrome: A Fatal Outcome after Kidney and Liver Transplantation Performed to Correct Factor H Gene Mutation. American Journal of Transplantation, 2005, 5, 1146-1150.	4.7	118
236	The Nrf2 pathway in the progression of renal disease. Nephrology Dialysis Transplantation, 2014, 29, i19-i24.	0.7	117
237	Implications of the initial mutations in membrane cofactor protein (MCP; CD46) leading to atypical hemolytic uremic syndrome. Molecular Immunology, 2007, 44, 111-122.	2.4	116
238	Rationaleâ€"Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT): Evolving the management of cardiovascular risk in patients with chronic kidney disease. American Heart Journal, 2005, 149, 408-413.	3.0	115
239	Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. American Journal of Physiology - Renal Physiology, 2009, 297, F1448-F1456.	2.8	115
240	Albuminuria and blood pressure, independent targets for cardioprotective therapy in patients with diabetes and nephropathy: a post hoc analysis of the combined RENAAL and IDNT trials. European Heart Journal, 2011, 32, 1493-1499.	2.2	115
241	Effect of Angiotensin-Converting Enzyme Inhibition on Glomerular Basement Membrane Permeability and Distribution of Zonula Occludens-1 in MWF Rats. Journal of the American Society of Nephrology: JASN, 2000, 11, 477-489.	0.5	115
242	Drug-Induced Thrombotic Microangiopathy. Drug Safety, 2001, 24, 491-501.	3.1	114
243	Efficacy of coupled plasma filtration adsorption (CPFA) in patients with septic shock: A multicenter randomised controlled clinical trial. BMJ Open, 2014, 4, e003536.	2.1	114
244	Adaptations and Lessons in the Province of Bergamo. New England Journal of Medicine, 2020, 382, e71.	29.6	113
245	Angiotensin-converting-enzyme inhibition therapy in altitude polycythaemia: a prospective randomised trial. Lancet, The, 2002, 359, 663-666.	11.9	112
246	Selective impairment of gene expression and assembly of nephrin in human diabetic nephropathy. Kidney International, 2004, 65, 2193-2200.	5.3	112
247	Human Amniotic Fluid Stem Cell Preconditioning Improves Their Regenerative Potential. Stem Cells and Development, 2012, 21, 1911-1923.	2.1	112
248	Endothelins in the control of cardiovascular and renal function. Lancet, The, 1993, 342, 589-593.	11.9	110
249	Favorable Long-Term Outcome after Liver-Kidney Transplant for Recurrent Hemolytic Uremic Syndrome Associated with a Factor H Mutation. American Journal of Transplantation, 2006, 6, 1948-1952.	4.7	110
250	Role of endothelium-derived nitric oxide in the bleeding tendency of uremia.. Journal of Clinical Investigation, 1990, 86, 1768-1771.	6.5	110
251	Platelet hyperaggregability and the nephrotic syndrome. Thrombosis Research, 1979, 16, 345-354.	1.7	109
252	Proximal tubular cells promote fibrogenesis by TGF-Î²1â€"mediated induction of peritubular myofibroblasts. Kidney International, 2002, 61, 2066-2077.	5.3	109

#	Article	IF	Citations
253	Residual plasmatic activity of ADAMTS13 is correlated with phenotype severity in congenital thrombotic thrombocytopenic purpura. Blood, 2012, 120, 440-448.	1.4	109
254	A Novel Strategy to Enhance Mesenchymal Stem Cell Migration Capacity and Promote Tissue Repair in an Injury Specific Fashion. Cell Transplantation, 2013, 22, 423-436.	2.5	109
255	Binding of Complement Factor H to Endothelial Cells Is Mediated by the Carboxy-Terminal Glycosaminoglycan Binding Site. American Journal of Pathology, 2005, 167, 1173-1181.	4.0	108
256	The pathophysiology and management of thrombotic thrombocytopenic purpura. European Journal of Haematology, 1996, 56, 191-207.	2.2	108
257	Shiga toxin-2 triggers endothelial leukocyte adhesion and transmigration via NF-Î°B dependent up-regulation of IL-8 and MCP-11. Kidney International, 2002, 62, 846-856.	5.3	107
258	ACE inhibition reduces glomerulosclerosis and regenerates glomerular tissue in a model of progressive renal disease. Kidney International, 2006, 69, 1124-1130.	5.3	107
259	Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood, 2012, 119, 3269-3275.	1.4	107
260	Translating the basic knowledge of mitochondrial functions to metabolic therapy: role of L-carnitine. Translational Research, 2013, 161, 73-84.	5.1	107
261	Prostacyclin and human foetal circulation. Prostaglandins, 1979, 18, 341-348.	1.1	105
262	Nature and extent of glomerular injury induced by cyclosporine in heart transplant patients. Kidney International, 1991, 40, 243-250.	5.3	105
263	RISK OF NONMELANOMA SKIN CANCER IN ITALIAN ORGAN TRANSPLANT RECIPIENTS. A REGISTRY-BASED STUDY. Transplantation, 2000, 70, 1479-1484.	1.0	104
264	Ameliorating Hypertension and Insulin Resistance in Subjects at Increased Cardiovascular Risk. Hypertension, 2009, 54, 567-574.	4.9	104
265	Challenges to achieving clinical transplantation tolerance. Journal of Clinical Investigation, 2001, 108, 943-948.	6.5	103
266	Effect of combining ACE inhibitor and statin in severe experimental nephropathy. Kidney International, 2002, 61, 1635-1645.	5.3	103
267	Adriamycin-Induced Glomerulosclerosis in the Rat. American Journal of Kidney Diseases, 1986, 7, 12-19.	1.9	102
268	Inhibiting Angiotensin-Converting Enzyme Promotes Renal Repair by Limiting Progenitor Cell Proliferation and Restoring the Glomerular Architecture. American Journal of Pathology, 2011, 179, 628-638.	4.0	101
269	Blocking both type A and B endothelin receptors in the kidney attenuates renal injury and prolongs survival in rats with remnant kidney. American Journal of Kidney Diseases, 1996, 27, 416-423.	1.9	99
270	Magnetic resonance imaging biomarkers for chronic kidney disease: a position paper from the European Cooperation in Science and Technology Action PARENCHIMA. Nephrology Dialysis Transplantation, 2018, 33, ii4-ii14.	0.7	99

#	Article	IF	Citations
271	PROSTACYCLIN-LIKE ACTIVITY AND BLEEDING IN RENAL FAILURE. Lancet, The, 1977, 310, 1195-1197.	11.9	98
272	Recent Progress in the Pathophysiology and Treatment of FSGS Recurrence. American Journal of Transplantation, 2013, 13, 266-274.	4.7	98
273	Immunosuppressive treatment for idiopathic membranous nephropathy: A systematic review. American Journal of Kidney Diseases, 2004, 44, 385-401.	1.9	97
274	Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition.. Journal of Clinical Investigation, 1987, 79, 1788-1797.	6.5	97
275	Cluster Analysis Identifies Distinct Pathogenetic Patterns in C3 Glomerulopathies/Immune Complexâ€“Mediated Membranoproliferative GN. Journal of the American Society of Nephrology: JASN, 2018, 29, 283-294.	0.5	96
276	Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group. Blood, 2020, 136, 2103-2117.	1.4	96
277	Effect of Cyclosporin A on prostacyclin synthesis by vascular tissue. Thrombosis Research, 1983, 32, 373-379.	1.7	95
278	Thromboxane synthesis and action within the kidney. Kidney International, 1992, 41, 1483-1493.	5.3	95
279	Sirolimus Versus Cyclosporine Therapy Increases Circulating Regulatory T Cells, But Does Not Protect Renal Transplant Patients Given Alemtuzumab Induction From Chronic Allograft Injury. Transplantation, 2007, 84, 956-964.	1.0	95
280	Extracellular vesicles derived from T regulatory cells suppress T cell proliferation and prolong allograft survival. Scientific Reports, 2017, 7, 11518.	3.4	95
281	Long-term follow-up of recovered patients with COVID-19. Lancet, The, 2021, 397, 173-175.	11.9	95
282	Verotoxin-1â€“induced up-regulation of adhesive molecules renders microvascular endothelial cells thrombogenic at high shear stress. Blood, 2001, 98, 1828-1835.	1.4	94
283	Shigatoxin-Induced Endothelin-1 Expression in Cultured Podocytes Autocrinally Mediates Actin Remodeling. American Journal of Pathology, 2006, 169, 1965-1975.	4.0	94
284	Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study. Journal of Hypertension, 2006, 24, 403-408.	0.5	94
285	Progression of renal injury toward interstitial inflammation and glomerular sclerosis is dependent on abnormal protein filtration. Nephrology Dialysis Transplantation, 2015, 30, 706-712.	0.7	94
286	Italy's first wave of the COVID-19 pandemic has ended: no excess mortality in May, 2020. Lancet, The, 2020, 396, e27-e28.	11.9	94
287	Reversible Activation Defect of the Platelet Glycoprotein IIb-IIIa Complex in Patients With Uremia. American Journal of Kidney Diseases, 1993, 22, 668-676.	1.9	93
288	Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood, 1995, 86, 4553-4558.	1.4	93

#	Article	IF	Citations
289	Nature and mediators of renal lesions in kidney transplant patients given cyclosporine for more than one year. Kidney International, 1999, 55, 674-685.	5.3	93
290	Podocyte Repopulation Contributes to Regression of Glomerular Injury Induced by Ace Inhibition. American Journal of Pathology, 2009, 174, 797-807.	4.0	93
291	Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: A post hoc analysis of RENAAL. Kidney International, 2006, 69, 1675-1682.	5.3	92
292	Renal progenitors derived from human iPSCs engraft and restore function in a mouse model of acute kidney injury. Scientific Reports, 2015, 5, 8826.	3.4	92
293	Chronic Proteinuric Nephropathies. II. Outcomes and Response to Treatment in a Prospective Cohort of 352 Patients. Journal of the American Society of Nephrology: JASN, 2000, 11, 88-96.	0.5	92
294	Imaging of the Porous Ultrastructure of the Glomerular Epithelial Filtration Slit. Journal of the American Society of Nephrology: JASN, 2010, 21, 2081-2089.	0.5	91
295	Mesenchymal stem cell therapy promotes renal repair by limiting glomerular podocyte and progenitor cell dysfunction in adriamycin-induced nephropathy. American Journal of Physiology - Renal Physiology, 2012, 303, F1370-F1381.	2.8	90
296	Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects. American Journal of Physiology - Renal Physiology, 2013, 304, F808-F819.	2.8	90
297	C-440T/T-331C polymorphisms in theUGT1A9gene affect the pharmacokinetics of mycophenolic acid in kidney transplantation. Pharmacogenomics, 2007, 8, 1127-1141.	1.3	89
298	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.	4.9	89
299	A Novel Atypical Hemolytic Uremic Syndromeâ€“Associated Hybrid CFHR1/CFH Gene Encoding a Fusion Protein That Antagonizes Factor Hâ€“Dependent Complement Regulation. Journal of the American Society of Nephrology: JASN, 2015, 26, 209-219.	0.5	89
300	Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease. Diabetes, Obesity and Metabolism, 2019, 21, 1199-1208.	4.5	89
301	Prevention of chronic kidney and vascular disease: Toward global health equityâ€”The Bellagio 2004 Declaration. Kidney International, 2005, 68, S1-S6.	5.3	87
302	Relation between ADAMTS13 activity and ADAMTS13 antigen levels in healthy donors and patients with thrombotic microangiopathies (TMA). Thrombosis and Haemostasis, 2006, 95, 212-220.	3.4	87
303	Successful Liver-Kidney Transplantation in Two Children With aHUS Caused by a Mutation in Complement Factor H. American Journal of Transplantation, 2007, 8, 071105081616017-???.	4.7	86
304	MicroRNA-324-3p Promotes Renal Fibrosis and Is a Target of ACE Inhibition. Journal of the American Society of Nephrology: JASN, 2012, 23, 1496-1505.	0.5	86
305	Thrombotic Thrombocytopenic Purpura and Related Disorders. Hematology/Oncology Clinics of North America, 1990, 4, 219-241.	1.9	85
306	Rituximab as pre-emptive treatment in patients with thrombotic thrombocytopenic purpura and evidence of anti-ADAMTS13 autoantibodies. Thrombosis and Haemostasis, 2009, 101, 233-238.	3.4	85

#	Article	IF	Citations
307	THE ACUTE EFFECT OF FK506 AND CYCLOSPORINE ON ENDOTHELIAL CELL FUNCTION AND RENAL VASCULAR RESISTANCE. Transplantation, 1992, 54, 775-779.	1.0	84
308	Rituximab for Idiopathic Membranous Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 738-748.	4.3	84
309	Taming the chronic kidney disease epidemic: a global view of surveillance efforts. Kidney International, 2014, 86, 246-250.	5.3	84
310	Measurable Urinary Albumin Predicts Cardiovascular Risk among Normoalbuminuric Patients with Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2012, 23, 1717-1724.	0.5	83
311	Plasmapheresis in the treatment of acute renal failure in multiple myeloma. American Journal of Medicine, 1979, 66, 684-688.	1.4	82
312	Permselective Dysfunction of Podocyte-Podocyte Contact upon Angiotensin II Unravels the Molecular Target for Renoprotective Intervention. American Journal of Pathology, 2006, 168, 1073-1085.	4.0	82
313	Timed Urine Collections Are Not Needed to Measure Urine Protein Excretion in Clinical Practice. American Journal of Kidney Diseases, 2006, 47, 1-7.	1.9	82
314	Genetic testing in the diagnosis of chronic kidney disease: recommendations for clinical practice. Nephrology Dialysis Transplantation, 2022, 37, 239-254.	0.7	82
315	Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: Implications for dialysis hypotension. American Journal of Kidney Diseases, 1998, 32, 115-124.	1.9	81
316	Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thrombosis and Haemostasis, 2005, 93, 443-452.	3.4	81
317	Prevention of Transplant Rejection. Drugs, 1997, 54, 533-570.	10.8	80
318	Key fibrogenic mediators: old players. Reninâ€“angiotensin system. Kidney International Supplements, 2014, 4, 58-64.	12.5	80
319	Sirt3 Deficiency Shortens Life Span and Impairs Cardiac Mitochondrial Function Rescued by Opa1 Gene Transfer. Antioxidants and Redox Signaling, 2019, 31, 1255-1271.	5.4	80
320	Pancreas and kidney/pancreas transplants: experimental medicine or real improvement?. Lancet, The, 1994, 343, 27-31.	11.9	79
321	Present and future drug treatments for chronic kidney diseases: evolving targets in renoprotection. Nature Reviews Drug Discovery, 2008, 7, 936-953.	60.2	79
322	Glomerular hyperfiltration. Nature Reviews Nephrology, 2022, 18, 435-451.	9.3	79
323	Dose-effect and pharmacokinetics of estrogens given to correct bleeding time in uremia. Kidney International, 1988, 34, 853-858.	5.3	78
324	Renoprotective effect of contemporary blocking of angiotensin II and endothelin-1 in rats with membranous nephropathy1. Kidney International, 1998, 54, 353-359.	5.3	78

#	Article	IF	Citations
325	In Kidney Transplant Patients, Alemtuzumab but Not Basiliximab/Low-Dose Rabbit Anti-Thymocyte Globulin Induces B Cell Depletion and Regeneration, Which Associates with a High Incidence of De Novo Donor-Specific Anti-HLA Antibody Development. Journal of Immunology, 2013, 191, 2818-2828.	0.8	77
326	An ExÂVivo Test of Complement Activation on Endothelium for Individualized Eculizumab Therapy in Hemolytic Uremic Syndrome. American Journal of Kidney Diseases, 2019, 74, 56-72.	1.9	77
327	Renal Expression of FGF23 in Progressive Renal Disease of Diabetes and the Effect of Ace Inhibitor. PLoS ONE, 2013, 8, e70775.	2.5	77
328	Application of newer clearance techniques for the determination of glomerular filtration rate. Current Opinion in Nephrology and Hypertension, 1998, 7, 675-680.	2.0	76
329	ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. Kidney International, 2000, 57, 274-281.	5.3	76
330	Effect of angiotensin II antagonism on the regression of kidney disease in the rat. Kidney International, 2002, 62, 885-894.	5.3	76
331	Altered platelet and vascular prostaglandin-generation in patients with renal failure and prolonged bleeding times. Thrombosis Research, 1978, 13, 1007-1015.	1.7	75
332	Pharmacokinetics help optimizing mycophenolate mofetil dosing in kidney transplant patients. Clinical Transplantation, 2001, 15, 402-409.	1.6	75
333	Angiotensin-Converting Enzyme Inhibition and Renal Protection in Nondiabetic Patients: The Data of the Meta-Analyses. Journal of the American Society of Nephrology: JASN, 2005, 16, S58-S63.	0.5	75
334	Thrombotic Thrombocytopenic Purpura: Evidence That Infusion Rather Than Removal of Plasma Induces Remission of the Disease. American Journal of Kidney Diseases, 1993, 21, 314-318.	1.9	74
335	The renoprotective properties of angiotensin-converting enzyme inhibitors in a chronic model of membranous nephropathy are solely due to the inhibition of angiotensin II: Evidence based on comparative studies with a receptor antagonist. American Journal of Kidney Diseases, 1997, 29, 254-264.	1.9	74
336	Influence of Co-Medication with Sirolimus or Cyclosporine on Mycophenolic Acid Pharmacokinetics in Kidney Transplantation. American Journal of Transplantation, 2005, 5, 2937-2944.	4.7	74
337	Recombinant Human Erythropoietin to Correct Uremic Bleeding. American Journal of Kidney Diseases, 1991, 18, 44-49.	1.9	73
338	Bindarit retards renal disease and prolongs survival in murine lupus autoimmune disease. Kidney International, 1998, 53, 726-734.	5.3	73
339	In-vitro and in-vivo consequences of mutations in the von Willebrand factor cleaving protease ADAMTS13 in thrombotic thrombocytopenic purpura. Thrombosis and Haemostasis, 2006, 96, 454-464.	3.4	73
340	Mesenchymal Stem Cells in Solid Organ Transplantation (MiSOT) Fourth Meeting. Transplantation, 2013, 96, 234-238.	1.0	73
341	Cardiovascular risk assessment in low-resource settings. Journal of Hypertension, 2014, 32, 951-960.	0.5	73
342	Radial Artery Remodeling in Response to Shear Stress Increase Within Arteriovenous Fistula for Hemodialysis Access. Endothelium: Journal of Endothelial Cell Research, 2003, 10, 95-102.	1.6	72

#	Article	IF	Citations
343	Effective CKD Care in European Countries: Challenges and Opportunities for Health Policy. American Journal of Kidney Diseases, 2015, 65, 15-25.	1.9	72
344	Abnormal protein traffic through the glomerular barrier induces proximal tubular cell dysfunction and causes renal injury. Current Opinion in Nephrology and Hypertension, 1995, 4, 339-342.	2.0	71
345	ACE inhibition improves glomerular size selectivity in patients with idiopathic membranous nephropathy and persistent nephrotic syndrome. American Journal of Kidney Diseases, 2000, 35, 381-391.	1.9	71
346	Imatinib ameliorates renal disease and survival in murine lupus autoimmune disease. Kidney International, 2006, 70, 97-103.	5.3	71
347	Chronic kidney disease: a research and public health priority. Nephrology Dialysis Transplantation, 2012, 27, iii19-iii26.	0.7	71
348	Renal and Systemic Effects of Calorie Restriction in Patients With Type 2 Diabetes With Abdominal Obesity: A Randomized Controlled Trial. Diabetes, 2017, 66, 75-86.	0.9	71
349	Nephropathy of type 1 and type 2 diabetes: diverse pathophysiology, same treatment?. Nephrology Dialysis Transplantation, 2000, 15, 1900-1902.	0.7	70
350	Long-Term Renal Allograft Function on a Tacrolimus-Based, Pred-Free Maintenance Immunosuppression Comparing Sirolimus vs. MMF+.. American Journal of Transplantation, 2006, 6, 1617-1623.	4.7	70
351	Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats. American Journal of Pathology, 2007, 170, 1165-1177.	4.0	70
352	Validation of a patient-specific hemodynamic computational model for surgical planning of vascular access in hemodialysis patients. Kidney International, 2013, 84, 1237-1245.	5.3	70
353	Mesenchymal stromal cells to promote solid organ transplantation tolerance. Current Opinion in Organ Transplantation, 2013, 18, 51-58.	1.5	70
354	Increased urinary excretion of thromboxane B2 and 2,3-dinor-TxB2 in cyclosporin A nephrotoxicity. Kidney International, 1988, 34, 164-174.	5.3	69
355	Platelets: An Update on Diagnosis and Management of Thrombocytopenic Disorders. Hematology American Society of Hematology Education Program, 2001, 2001, 282-305.	2.5	68
356	Effect of acetate-free biofiltration and bicarbonate hemodialysis on neutrophil activation. American Journal of Kidney Diseases, 2002, 40, 783-793.	1.9	68
357	Nephrotoxic aspects of cyclosporine. Transplantation Proceedings, 2004, 36, S234-S239.	0.6	68
358	MODERATE DOSES OF ASPIRIN AND RISK OF BLEEDING IN RENAL FAILURE. Lancet, The, 1986, 327, 414-416.	11.9	67
359	Advancement of Mesenchymal Stem Cell Therapy in Solid Organ Transplantation (MISOT). Transplantation, 2010, 90, 124-126.	1.0	67
360	Unbalanced prostaglandin synthesis and plasma factors in uraemic bleeding. A hypothesis. Thrombosis Research, 1978, 13, 531-536.	1.7	66

#	Article	IF	Citations
361	Familial deficiency of a plasma factor stimulating vascular prostacyclin activity. Thrombosis Research, 1979, 16, 517-525.	1.7	66
362	Increased renal endothelin production in rats with reduced renal mass. American Journal of Physiology - Renal Physiology, 1991, 260, F331-F339.	2.8	66
363	Generation of functional podocytes from human induced pluripotent stem cells. Stem Cell Research, 2016, 17, 130-139.	0.7	66
364	Haemolytic uraemic syndrome: therapeutic effect of plasma infusion.. The BMJ, 1982, 285, 1304-1306.	0.6	65
365	The Role of Protein Traffic in the Progression of Renal Diseases. Annual Review of Medicine, 2000, 51, 315-327.	11.9	65
366	Diverse Effects of Increasing Lisinopril Doses on Lipid Abnormalities in Chronic Nephropathies. Circulation, 2003, 107, 586-592.	6.2	65
367	Membranous Nephropathy Associated With IgG4-Related Disease. American Journal of Kidney Diseases, 2011, 58, 272-275.	1.9	65
368	Thymic Dendritic Cells Express Inducible Nitric Oxide Synthase and Generate Nitric Oxide in Response to Self- and Alloantigens. Journal of Immunology, 2000, 164, 4649-4658.	0.8	64
369	Proteinuria predicting outcome in renal disease: Nondiabetic nephropathies (REIN). Kidney International, 2004, 66, S90-S96.	5.3	64
370	Toward MSC in Solid Organ Transplantation: 2008 Position Paper of the MISOT Study Group. Transplantation, 2009, 88, 614-619.	1.0	64
371	Cardiovascular complications in atypical haemolytic uraemic syndrome. Nature Reviews Nephrology, 2014, 10, 174-180.	9.3	64
372	Î²-Arrestin-1 Drives Endothelin-1â€“Mediated Podocyte Activation and Sustains Renal Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 523-533.	0.5	64
373	Dramatic effects of eculizumab in a child with diffuse proliferative lupus nephritis resistant to conventional therapy. Pediatric Nephrology, 2015, 30, 167-172.	1.7	64
374	Association Between Circulating Levels of C-Reactive Protein and Interleukin-6 and Risk of Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 818-824.e6.	4.6	64
375	Maternal and environmental risk factors for neonatal AKI and its long-term consequences. Nature Reviews Nephrology, 2018, 14, 688-703.	9.3	64
376	Antihypertensive treatment and risk of cancer: an individual participant data meta-analysis. Lancet Oncology, The, 2021, 22, 558-570.	10.6	64
377	CTLA4Ig Gene Transfer Prolongs Survival and Induces Donor-Specific Tolerance in a Rat Renal Allograft. Journal of the American Society of Nephrology: JASN, 2000, 11, 747-752.	0.5	64
378	The antiproteinuric effect of angiotensin antagonism in human IgA nephropathy is potentiated by indomethacin.. Journal of the American Society of Nephrology: JASN, 1998, 9, 2308-2317.	0.5	64

#	Article	IF	Citations
379	Size regulation of von Willebrand factorâ€“mediated platelet thrombi by ADAMTS13 in flowing blood. Blood, 2006, 107, 1943-1950.	1.4	63
380	Renal progenitors in non-diabetic and diabetic nephropathies. Trends in Endocrinology and Metabolism, 2013, 24, 13-20.	6.9	63
381	Long-Term Treatment With Either Enalapril or Nitrendipine Stabilizes Albuminuria and Increases Glomerular Filtration Rate in Non- Insulin-Dependent Diabetic Patients. American Journal of Kidney Diseases, 1994, 24, 753-761.	1.9	62
382	ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. American Journal of Kidney Diseases, 1999, 34, 626-632.	1.9	62
383	Propionyl-l-carnitine prevents renal function deterioration due to ischemia/reperfusion. Kidney International, 2002, 61, 1064-1078.	5.3	62
384	Involvement of renal tubular tollâ€like receptor 9 in the development of tubulointerstitial injury in systemic lupus. Arthritis and Rheumatism, 2007, 56, 1569-1578.	6.8	62
385	Effects of verapamil added-on trandolapril therapy in hypertensive type 2 diabetes patients with microalbuminuria: the BENEDICT-B randomized trial. Journal of Hypertension, 2011, 29, 207-216.	0.5	62
386	Successful Split Liver-Kidney Transplant for Factor H Associated Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 201-206.	4.3	61
387	Baseline Characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2009, 54, 59-69.	1.9	61
388	Nature and Mediators of Parietal Epithelial Cell Activation in Glomerulonephritides of Human and Rat. American Journal of Pathology, 2013, 183, 1769-1778.	4.0	61
389	Prevention and Treatment of Pregnancy-Associated Hypertension: What Have We Learned in the Last 10 Years?. American Journal of Kidney Diseases, 1991, 18, 285-305.	1.9	60
390	Angiotensin receptors as determinants of life span. Pflugers Archiv European Journal of Physiology, 2010, 459, 325-332.	2.8	60
391	Early reninâ€angiotensin system intervention is more beneficial than late intervention in delaying endâ€stage renal disease in patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2016, 18, 64-71.	4.5	60
392	Subcutaneous desmopressin (DDAVP) shortens the bleeding time in uremia. American Journal of Hematology, 1989, 31, 32-35.	4.2	59
393	Three-dimensional analysis of glomerular morphology in patients with subtotal nephrectomy. Kidney International, 1995, 48, 155-162.	5.3	59
394	Effects of phosphate intake on distribution of type II Na/Pi cotransporter mRNA in rat kidney. Kidney International, 1999, 55, 976-983.	5.3	59
395	Computational Fluid Dynamics of a Vascular Access Case for Hemodialysis. Journal of Biomechanical Engineering, 2001, 123, 284-292.	1.3	59
396	Therapeutic Drug Monitoring of Sirolimus: Effect of Concomitant Immunosuppressive Therapy and Optimization of Drug Dosing. American Journal of Transplantation, 2004, 4, 1345-1351.	4.7	59

#	Article	IF	Citations
397	Managing and preventing atypical hemolytic uremic syndrome recurrence after kidney transplantation. Current Opinion in Nephrology and Hypertension, 2013, 22, 704-712.	2.0	59
398	Long-Term Clinical and Immunological Profile of Kidney Transplant Patients Given Mesenchymal Stromal Cell Immunotherapy. Frontiers in Immunology, 2018, 9, 1359.	4.8	59
399	Nephropathic nature of proteinuria. Current Opinion in Nephrology and Hypertension, 1999, 8, 655-663.	2.0	59
400	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood, 1989, 74, 978-983.	1.4	59
401	From Pharmacokinetics to Pharmacogenomics: A New Approach to Tailor Immunosuppressive Therapy. American Journal of Transplantation, 2004, 4, 299-310.	4.7	58
402	A COMPARATIVE PROSPECTIVE STUDY OF TWO AVAILABLE SOLUTIONS FOR KIDNEY AND LIVER PRESERVATION. Transplantation, 2004, 77, 1540-1545.	1.0	58
403	The Regenerative Potential of Stem Cells in Acute Renal Failure. Cell Transplantation, 2006, 15, 111-117.	2.5	58
404	V1/V2 Vasopressin receptor antagonism potentiates the renoprotection of reninâ€“angiotensin system inhibition in rats with renal mass reduction. Kidney International, 2009, 76, 960-967.	5.3	58
405	Burden of CKD, Proteinuria, and Cardiovascular Risk Among Chinese, Mongolian, and Nepalese Participants in the International Society of Nephrology Screening Programs. American Journal of Kidney Diseases, 2010, 56, 915-927.	1.9	58
406	Interaction between Multimeric von Willebrand Factor and Complement: A Fresh Look to the Pathophysiology of Microvascular Thrombosis. Journal of Immunology, 2017, 199, 1021-1040.	0.8	58
407	Longitudinal Estimated GFR Trajectories in Patients With and Without Type 2 Diabetes and Nephropathy. American Journal of Kidney Diseases, 2018, 71, 91-101.	1.9	58
408	Blunted excretory response to atrial natriuretic peptide in experimental nephrosis. Kidney International, 1989, 36, 57-64.	5.3	57
409	Malignant vascular disease of the kidney: Nature of the lesions, mediators of disease progression, and the case for bilateral nephrectomy. American Journal of Kidney Diseases, 1996, 27, 459-475.	1.9	57
410	How renal cytokines and growth factors contribute to renal disease progression. American Journal of Kidney Diseases, 2001, 37, S21-S24.	1.9	57
411	Rituximab prevents recurrence of thrombotic thrombocytopenic purpura: a case report. Blood, 2005, 106, 925-928.	1.4	57
412	Worsening kidney function in decompensated heart failure: treat the heart, don't mind the kidney. European Heart Journal, 2011, 32, 2476-2478.	2.2	57
413	Clinical Translation of Mesenchymal Stromal Cell Therapies in Nephrology. Journal of the American Society of Nephrology: JASN, 2018, 29, 362-375.	0.5	57
414	Whole-Blood Calcineurin Activity Is Not Predicted by Cyclosporine Blood Concentration in Renal Transplant Recipients. Clinical Chemistry, 2001, 47, 1679-1687.	3.4	56

#	Article	IF	Citations
415	Distinct cardiac and renal effects of ET_Areceptor antagonist and ACE inhibitor in experimental type 2 diabetes. American Journal of Physiology - Renal Physiology, 2011, 301, F1114-F1123.	2.8	56
416	MicroRNA-184 is a downstream effector of albuminuria driving renal fibrosis in rats with diabetic nephropathy. Diabetologia, 2017, 60, 1114-1125.	6.4	56
417	Antibody-mediated extraction/negative-ion chemical ionization mass spectrometric measurement of thromboxane B2 and 2,3-dinor-thromboxane B2 in human and rat urine. Analytical Biochemistry, 1987, 163, 255-262.	2.4	55
418	Indomethacin reduces proteinuria in passive Heymann nephritis in rats. Kidney International, 1987, 31, 1335-1343.	5.3	55
419	Pharmacologic control of angiotensin II ameliorates renal disease while reducing renal TGF-beta in experimental mesangioproliferative glomerulonephritis. American Journal of Kidney Diseases, 1998, 31, 453-463.	1.9	55
420	A report with consensus statements of the International Society of Nephrology 2004 Consensus Workshop on Prevention of Progression of Renal Disease, Hong Kong, June 29, 2004. Kidney International, 2005, 67, S2-S7.	5.3	55
421	Mesenchymal Stromal Cells for Transplant Tolerance. Frontiers in Immunology, 2019, 10, 1287.	4.8	55
422	Renal epidemiology. The first clinical and epidemiological programme on renal disease in Bolivia: a model for prevention and early diagnosis of renal diseases in the developing countries. Nephrology Dialysis Transplantation, 1998, 13, 3034-3036.	0.7	54
423	Experimental Evaluation of Kidney Regeneration by Organ Scaffold Recellularization. Scientific Reports, 2017, 7, 43502.	3.4	54
424	SEQUENTIAL MONITORING OF URINE-SOLUBLE INTERLEUKIN 2 RECEPTOR AND INTERLEUKIN 6 PREDICTS ACUTE REJECTION OF HUMAN RENAL ALLOGRAFTS BEFORE CLINICAL OR LABORATORY SIGNS OF RENAL DYSFUNCTION. Transplantation, 1997, 63, 1508-1514.	1.0	54
425	Nephrotoxicity of increased glomerular protein traffic. Nephrology Dialysis Transplantation, 1999, 14, 304-312.	0.7	53
426	Vasopeptidase inhibitor restores the balance of vasoactive hormones in progressive nephropathy. Kidney International, 2004, 66, 1959-1965.	5.3	53
427	Prevention programmes of progressive renal disease in developing nations (Review Article). Nephrology, 2006, 11, 321-328.	1.6	53
428	Pharmacokinetics of Mycophenolate Sodium and Comparison with the Mofetil Formulation in Stable Kidney Transplant Recipients. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 1147-1155.	4.3	53
429	Effects of Rituximab on Morphofunctional Abnormalities of Membranous Glomerulopathy. Clinical Journal of the American Society of Nephrology: CJASN, 2008, 3, 1652-1659.	4.3	53
430	Shiga Toxin Promotes Podocyte Injury in Experimental Hemolytic Uremic Syndrome via Activation of the Alternative Pathway of Complement. Journal of the American Society of Nephrology: JASN, 2014, 25, 1786-1798.	0.5	53
431	Functional Human Podocytes Generated in Organoids from Amniotic Fluid Stem Cells. Journal of the American Society of Nephrology: JASN, 2016, 27, 1400-1411.	0.5	53
432	Manipulating Sirtuin 3 pathway ameliorates renal damage in experimental diabetes. Scientific Reports, 2020, 10, 8418.	3.4	53

#	Article	IF	Citations
433	Bleeding in renal failure: is von Willebrand factor implicated?. The BMJ, 1977, 2, 359-361.	0.6	52
434	Abnormal permeability to proteins and glomerular lesions: A meta-analysis of experimental and human studies. American Journal of Kidney Diseases, 1996, 27, 34-41.	1.9	52
435	Is ADAMTS-13 deficiency specific for thrombotic thrombocytopenic purpura? No. Journal of Thrombosis and Haemostasis, 2003, 1, 632-634.	4.0	52
436	Thrombotic Thrombocytopenic Purpura-Then and Now. Seminars in Thrombosis and Hemostasis, 2006, 32, 081-089.	2.7	52
437	Two Patients With History of STEC-HUS, Posttransplant Recurrence and Complement Gene Mutations. American Journal of Transplantation, 2013, 13, 2201-2206.	4.7	52
438	Paricalcitol for Secondary Hyperparathyroidism in Renal Transplantation. Journal of the American Society of Nephrology: JASN, 2015, 26, 1205-1214.	0.5	52
439	Low-protein diet prevents glomerular damage in adriamycin-treated rats. Kidney International, 1985, 28, 21-27.	5.3	51
440	Enhanced proteolysis of plasma von Willebrand factor in thrombotic thrombocytopenic purpura and the hemolytic uremic syndrome. Blood, 1989, 74, 978-983.	1.4	51
441	Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney International, 1999, 55, 984-994.	5.3	51
442	Correction of Anemia â€" Payoffs and Problems. New England Journal of Medicine, 2006, 355, 2144-2146.	29.6	51
443	Diets for patients with chronic kidney disease, should we reconsider?. BMC Nephrology, 2016, 17, 80.	1.8	51
444	Functional significance of exaggerated renal thromboxane A2 synthesis induced by cyclosporin A. American Journal of Physiology - Renal Physiology, 1986, 251, F581-F587.	2.8	50
445	Human placenta expresses endothelin gene and corresponding protein is excreted in urine in increasing amounts during normal pregnancy. American Journal of Obstetrics and Gynecology, 1991, 164, 844-848.	1.3	50
446	Increased nitric oxide formation in recurrent thrombotic microangiopathies: A possible mediator of microvascular injury. American Journal of Kidney Diseases, 1996, 27, 790-796.	1.9	50
447	Mycophenolate mofetil combined with a cyclooxygenase-2 inhibitor ameliorates murine lupus nephritis. Kidney International, 2001, 60, 653-663.	5.3	50
448	Kidney failure: aims for the next 10 years and barriers to success. Lancet, The, 2013, 382, 353-362.	11.9	50
449	C3a receptor blockade protects podocytes from injury in diabetic nephropathy. Journal of Clinical Investigation, 2020, 5, .	6.5	50
450	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Platelet Aggregation. Frontiers in Immunology, 2022, 13, 827146.	4.8	50

#	Article	IF	Citations
451	Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. Kidney International, 1987, 31, 1248-1256.	5.3	49
452	Atrial Natriuretic Peptide and Prostacyclin Synergistically Mediate Hyperfiltration and Hyperperfusion of Diabetic Rats. Diabetes, 1992, 41, 533-538.	0.9	49
453	Plasma Exchange in Children With Hemolytic-Uremic Syndrome at Risk of Poor Outcome. American Journal of Kidney Diseases, 1993, 22, 264-266.	1.9	49
454	Adding a statin to a combination of ACE inhibitor and ARB normalizes proteinuria in experimental diabetes, which translates into full renoprotection. American Journal of Physiology - Renal Physiology, 2010, 299, F1203-F1211.	2.8	49
455	Podocyte dysfunction in atypical haemolytic uraemic syndrome. Nature Reviews Nephrology, 2015, 11, 245-252.	9.3	49
456	Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. Kidney International, 2019, 96, 555-567.	5.3	49
457	PAF mediates neutrophil adhesion to thrombin or TNF-stimulated endothelial cells under shear stress. American Journal of Physiology - Cell Physiology, 1995, 269, C42-C47.	4.5	48
458	Cyclin-dependent kinase inhibition limits glomerulonephritis and extends lifespan of mice with systemic lupus. Arthritis and Rheumatism, 2007, 56, 1629-1637.	6.8	48
459	Rare diseases and effective treatments: are we delivering?. Lancet, The, 2015, 385, 750-752.	11.9	48
460	The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials. BMC Nephrology, 2016, 17, 141.	1.8	48
461	Long-term Effects of Octreotide on Liver Volume in Patients WithÂPolycystic Kidney and Liver Disease. Clinical Gastroenterology and Hepatology, 2016, 14, 1022-1030.e4.	4.6	48
462	Bilateral nephrectomy stopped disease progression in plasma-resistant hemolytic uremic syndrome with neurological signs and coma. Kidney International, 1996, 49, 282-286.	5.3	47
463	The future of renoprotection: Frustration and promises. Kidney International, 2003, 64, 1947-1955.	5.3	47
464	Sirolimus for calcineurin inhibitors in organ transplantation: contra. Kidney International, 2010, 78, 1068-1074.	5.3	47
465	Measuring and Estimating GFR and Treatment Effect in ADPKD Patients: Results and Implications of a Longitudinal Cohort Study. PLoS ONE, 2012, 7, e32533.	2.5	47
466	Characterization of a New DGKE Intronic Mutation in Genetically Unsolved Cases of Familial Atypical Hemolytic Uremic Syndrome. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1011-1019.	4.3	47
467	Long-term outcome of renal transplantation from octogenarian donors: A multicenter controlled study. American Journal of Transplantation, 2017, 17, 3159-3171.	4.7	47
468	Engineering the vasculature of decellularized rat kidney scaffolds using human induced pluripotent stem cell-derived endothelial cells. Scientific Reports, 2019, 9, 8001.	3.4	47

#	Article	IF	Citations
469	Octreotide-LAR in later-stage autosomal dominant polycystic kidney disease (ALADIN 2): A randomized, double-blind, placebo-controlled, multicenter trial. PLoS Medicine, 2019, 16, e1002777.	8.2	47
470	THROMBOTIC TENDENCY IN SYSTEMIC LUPUS ERYTHEMATOSUS. Lancet, The, 1981, 317, 719.	11.9	46
471	Plasmatic regulation of vascular prostacyclin in pregnancy.. British Medical Journal, 1981, 282, 512-514.	0.8	46
472	Strategies for national health care systems in emerging countries: The case of screening and prevention of renal disease progression in Bolivia. Kidney International, 2005, 68, S87-S94.	5.3	46
473	The Toll-IL-1R Member Tir8/SIGIRR Negatively Regulates Adaptive Immunity against Kidney Grafts. Journal of Immunology, 2009, 183, 4249-4260.	0.8	46
474	Acute renal failure: an unacceptable death sentence globally. Lancet, The, 2013, 382, 2041-2042.	11.9	46
475	C5 Convertase Blockade in Membranoproliferative Glomerulonephritis: A Single-Arm Clinical Trial. American Journal of Kidney Diseases, 2019, 74, 224-238.	1.9	46
476	PROSTACYCLIN GENERATION BY CULTURED ENDOTHELIAL CELLS IN HÃ†MOLYTIC URÃ†MIC SYNDROME. Lancet, The, 1980, 315, 656-657.	11.9	45
477	Angiotensin-Converting Enzyme nhibition Prevents Glomerular-Tubule Disconnection and Atrophy in Passive Heymann Nephritis, an Effect Not Observed with a Calcium Antagonist. American Journal of Pathology, 2001, 159, 1743-1750.	4.0	45
478	Progression of chronic kidney disease: insights from animal models. Current Opinion in Nephrology and Hypertension, 2006, 15, 250-257.	2.0	45
479	Biocompatibility and function of microencapsulated pancreatic islets. Acta Biomaterialia, 2006, 2, 221-227.	8.5	45
480	Any value of podocyte B7-1 as a biomarker in human MCD and FSGS?. American Journal of Physiology - Renal Physiology, 2016, 310, F335-F341.	2.8	45
481	Structural basis of diabetic nephropathy in microalbuminuric NIDDM patients: a light microscopy study. Diabetologia, 1996, 39, 1625-1628.	6.4	44
482	Experimental Goodpasture's syndrome in Wistar-Kyoto rats immunized with Î±3 chain of type IV collagen. Kidney International, 1998, 54, 1550-1561.	5.3	44
483	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	44
484	Changes in glomerular perm-selectivity induced by angiotensin II imply podocyte dysfunction and slit diaphragm protein rearrangement. Seminars in Nephrology, 2004, 24, 131-140.	1.5	44
485	Basiliximab Combined with Low-Dose Rabbit Anti-Human Thymocyte Globulin: A Possible Further Step toward Effective and Minimally Toxic T Cellâ€"Targeted Therapy in Kidney Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 546-554.	4.3	44
486	Glutamate and cortisolâ€"a critical confluence in PTSD?. Journal of Psychopharmacology, 2008, 22, 469-472.	4.1	44

#	Article	IF	Citations
487	Is the ONTARGET renal substudy actually off target?. Nature Reviews Nephrology, 2009, 5, 436-437.	9.3	44
488	Mesenchymal Stem Cells in Kidney Repair. Methods in Molecular Biology, 2016, 1416, 89-107.	0.7	44
489	Challenges to achieving clinical transplantation tolerance. Journal of Clinical Investigation, 2001, 108, 943-948.	6.5	44
490	PARATHYROID HORMONE INHIBITS HUMAN PLATELET FUNCTION. Lancet, The, 1981, 318, 1321-1323.	11.9	43
491	Direct podocyte damage in the single nephron leads to albuminuria in vivo. Kidney International, 1995, 47, 1078-1086.	5.3	43
492	Halting the Progression of Chronic Nephropathy. Journal of the American Society of Nephrology: JASN, 2002, 13, S190-S195.	0.5	43
493	DOPPLER ULTRASONOGRAPHY IN POSTTRANSPLANT RENAL ARTERY STENOSIS. Transplantation, 2003, 76, 147-153.	1.0	43
494	The role of chemokines in progressive renal disease. Frontiers in Bioscience - Landmark, 2009, Volume, 1815.	3.1	43
495	Ethical issues in dialysis therapy. Lancet, The, 2017, 389, 1851-1856.	11.9	43
496	Kidney volume measurement methods for clinical studies on autosomal dominant polycystic kidney disease. PLoS ONE, 2017, 12, e0178488.	2.5	43
497	Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor. International Journal of Cardiology, 2019, 278, 243-249.	1.6	43
498	Befriending the Hostile Tumor Microenvironment in CAR T-Cell Therapy. Frontiers in Immunology, 2020, 11, 618387.	4.8	43
499	Renoprotection by nitric oxide donor and lisinopril in the remnant kidney model. American Journal of Kidney Diseases, 1999, 33, 746-753.	1.9	42
500	Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies. Kidney International, 2001, 59, 286-294.	5.3	42
501	Insulin Resistance and Proliferative Retinopathy: A Cross-Sectional, Case-Control Study in 115 Patients with Type 2 Diabetes. Journal of Clinical Endocrinology and Metabolism, 2004, 89, 4371-4376.	3.5	42
502	Aging and the kidney. Current Opinion in Nephrology and Hypertension, 2011, 20, 312-317.	2.0	42
503	Common Elements in Rare Kidney Diseases: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2017, 92, 796-808.	5.3	42
504	Mesenchymal stromal cells for tolerance induction in organ transplantation. Human Immunology, 2018, 79, 304-313.	2.5	42

#	Article	IF	Citations
505	Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN. Frontiers in Immunology, 2018, 9, 2329.	4.8	42
506	A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. EClinicalMedicine, 2021, 37, 100941.	7.0	42
507	Albuminuria as early test for vascular disease. Lancet, The, 2005, 365, 556-557.	11.9	42
508	ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. American Journal of Physiology - Renal Physiology, 1999, 276, F457-F466.	2.8	41
509	Genetic analysis of the complement factor H related 5 gene in haemolytic uraemic syndrome. Molecular Immunology, 2007, 44, 1704-1708.	2.4	41
510	CD133+ renal stem cells always co-express CD24 in adult human kidney tissue. Stem Cell Research, 2014, 12, 828-829.	0.7	41
511	C5a and C5aR1 are key drivers of microvascular platelet aggregation in clinical entities spanning from aHUS to COVID-19. Blood Advances, 2022, 6, 866-881.	5.3	41
512	Prostacyclin and Thrombotic Microangiopathy. Seminars in Thrombosis and Hemostasis, 1980, 6, 391-394.	2.7	40
513	Cigarette smoking and renal function impairment. American Journal of Kidney Diseases, 1999, 33, 807-810.	1.9	40
514	Effect of the Urotensin Receptor Antagonist Palosuran in Hypertensive Patients With Type 2 Diabetic Nephropathy. Hypertension, 2010, 55, 1206-1209.	4.9	40
515	Variations of the angiotensin II type 1 receptor gene are associated with extreme human longevity. Age, 2013, 35, 993-1005.	2.9	40
516	Physiology and Pathophysiology of Nitric Oxide in Chronic Renal Disease. Proceedings of the Association of American Physicians, 1999, 111, 602-610.	2.3	40
517	A meta-analysis of GFR slope as a surrogate endpoint for kidney failure. Nature Medicine, 2023, 29, 1867-1876.	29.5	40
518	REDUCTION OF FETAL VASCULAR PROSTACYCLIN ACTIVITY IN PRE-ECLAMPSIA. Lancet, The, 1980, 316, 310.	11.9	39
519	Renoprotective effect of low iron diet and its consequence on glomerular hemodynamics. Kidney International, 1991, 39, 647-652.	5.3	39
520	Fractalkine and CX3CR1 Mediate Leukocyte Capture by Endothelium in Response to Shiga Toxin. Journal of Immunology, 2008, 181, 1460-1469.	0.8	39
521	Immunosuppressive treatment for focal segmental glomerulosclerosis in adults. The Cochrane Library, 2008, , CD003233.	2.8	39
522	Angiotensin II Contributes to Diabetic Renal Dysfunction in Rodents and Humans via Notch1/Snail Pathway. American Journal of Pathology, 2013, 183, 119-130.	4.0	39

#	Article	IF	Citations
523	Edema of the Nephrotic Syndrome: The Role of the Atrial Peptide System. American Journal of Kidney Diseases, 1993, 22, 355-366.	1.9	38
524	Computed Tomography Evaluation of Autosomal Dominant Polycystic Kidney Disease Progression. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 754-760.	4.3	38
525	Developing Regulatory-compliant Electronic Case Report Forms for Clinical Trials: Experience with The Demand Trial. Journal of the American Medical Informatics Association: JAMIA, 2009, 16, 404-408.	4.5	38
526	COVID-19 and lombardy: TESTing the impact of the first wave of the pandemic. EBioMedicine, 2020, 61, 103069.	5.9	38
527	Thromboxane A2 receptor blocking abrogates donor-specific unresponsiveness to renal allografts induced by thymic recognition of major histocompatibility allopeptides.. Journal of Experimental Medicine, 1994, 180, 1967-1972.	8.6	37
528	Ways to Boost Kidney Transplant Viability: A Real Need for the Best Use of Older Donors. American Journal of Transplantation, 2006, 6, 2543-2547.	4.7	37
529	Screening for chronic kidney disease in emerging countries: feasibility and hurdles. Nephrology Dialysis Transplantation, 2009, 24, 1355-1358.	0.7	37
530	The role of renin angiotensin system inhibition in kidney repair. Fibrogenesis and Tissue Repair, 2010, 3, 7.	3.2	37
531	Effects of Add-on Fluvastatin Therapy in Patients with Chronic Proteinuric Nephropathy on Dual Renin-Angiotensin System Blockade. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 1928-1938.	4.3	37
532	Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial. Lancet Diabetes and Endocrinology,the, 2013, 1, 19-27.	11.1	37
533	Regression of Renal Disease by Angiotensin II Antagonism Is Caused by Regeneration of Kidney Vasculature. Journal of the American Society of Nephrology: JASN, 2016, 27, 699-705.	0.5	37
534	Prevention and Treatment of Diabetic Retinopathy: Evidence from Clinical Trials and Perspectives. Current Diabetes Reviews, 2011, 7, 190-200.	1.3	37
535	The metabolism of arachidonic acid by platelets in nephrotic syndrome. Kidney International, 1984, 25, 671-676.	5.3	36
536	Renoprotective effects of renin-angiotensin-system inhibitors. Lancet, The, 2006, 367, 899-900.	11.9	36
537	Overview of randomised trials of ACE inhibitors. Lancet, The, 2006, 368, 555-556.	11.9	36
538	Treatment With Pegylated Interferon and Ribavirin for Hepatitis C Virus-associated Severe Cryoglobulinemia in a Liver/Kidney Transplant Recipient. Journal of Clinical Gastroenterology, 2007, 41, 216-220.	2.3	36
539	Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. British Journal of Dermatology, 2007, 157, 49-57.	1.7	36
540	Erythropoietin, but not the correction of anemia alone, protects from chronic kidney allograft injury. Kidney International, 2012, 81, 903-918.	5.3	36

#	Article	IF	Citations
541	Effect of Sirolimus on Disease Progression in Patients with Autosomal Dominant Polycystic Kidney Disease and CKD Stages 3b-4. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 785-794.	4.3	36
542	Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatric Nephrology, 2019, 34, 1311-1323.	1.7	36
543	Role of platelets in progressive glomerular diseases. Pediatric Nephrology, 1995, 9, 495-502.	1.7	35
544	Cellular basis of long-term organ transplant acceptance: Pivotal role of intrathymic clonal deletion and thymic dependence of bone marrow microchimerism-associated tolerance. American Journal of Kidney Diseases, 1998, 31, 197-212.	1.9	35
545	The hemolytic uremic syndromes. Current Opinion in Critical Care, 2005, 11, 487-492.	3.3	35
546	Lack of the Lectin-like Domain of Thrombomodulin Worsens Shiga Toxin-Associated Hemolytic Uremic Syndrome in Mice. Journal of Immunology, 2012, 189, 3661-3668.	0.8	35
547	Ofatumumab for multirelapsing membranous nephropathy complicated by rituximab-induced serum-sickness. BMJ Case Reports, 2020, 13, e232896.	0.5	35
548	At the peak of COVID-19 age and disease severity but not comorbidities are predictors of mortality: COVID-19 burden in Bergamo, Italy. Panminerva Medica, 2021, 63, 51-61.	0.8	35
549	Cyclosporine induces glomerulosclerosis: Three-dimensional definition of the lesions in a rat model of renal transplant. Kidney International, 1996, 49, 1283-1288.	5.3	34
550	Angiotensin-converting enzyme inhibitor therapy for non-diabetic progressive renal disease. Current Opinion in Nephrology and Hypertension, 1997, 6, 489-495.	2.0	34
551	Peripheral donor leukocytes prolong survival of rat renal allografts. Kidney International, 1999, 56, 1101-1112.	5.3	34
552	Beneficial effects of calcium channel blockade on acute glomerular hemodynamic changes induced by cyclosporine. American Journal of Kidney Diseases, 1999, 33, 267-275.	1.9	34
553	Adult nondiarrhea hemolytic uremic syndrome associated with shiga toxin escherichia coli O157:H7 bacteremia and urinary tract infection. American Journal of Kidney Diseases, 2003, 41, e4.1-e4.4.	1.9	34
554	Preventing Left Ventricular Hypertrophy by ACE Inhibition in Hypertensive Patients With Type 2 Diabetes. Diabetes Care, 2008, 31, 1629-1634.	9.0	34
555	Blood Pressure, Proteinuria, and Phosphate as Risk Factors for Progressive Kidney Disease: A Hypothesis. American Journal of Kidney Diseases, 2013, 62, 984-992.	1.9	34
556	Novel Biomarkers for Renal Diseases? None for the Moment (but One). SLAS Discovery, 2016, 21, 655-670.	2.7	34
557	Factor H Competitor Generated by Gene Conversion Events Associates with Atypical Hemolytic Uremic Syndrome. Journal of the American Society of Nephrology: JASN, 2018, 29, 240-249.	0.5	34
558	Ticlopidine prevents renal disease progression in rats with reduced renal mass. Kidney International, 1990, 37, 934-942.	5.3	33

#	Article	IF	Citations
559	Measurement of GFR with a single intravenous injection of nonradioactive iothalamate. Kidney International, 1992, 41, 1081-1084.	5.3	33
560	Dendritic Cells Genetically Engineered with Adenoviral Vector Encoding dnIKK2 Induce the Formation of Potent CD4+ T-Regulatory Cells. Transplantation, 2005, 79, 1056-1061.	1.0	33
561	Predictors of Atrasentan-Associated Fluid Retention and Change in Albuminuria in Patients with Diabetic Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 1568-1574.	4.3	33
562	Complement Alternative Pathway Deficiency in Recipients Protects Kidney Allograft From Ischemia/Reperfusion Injury and Alloreactive T Cell Response. American Journal of Transplantation, 2017, 17, 2312-2325.	4.7	33
563	Outcomes of patients with atypical haemolytic uraemic syndrome with native and transplanted kidneys treated with eculizumab: a pooledpost hocanalysis. Transplant International, 2017, 30, 1275-1283.	1.7	33
564	Following an Initial Decline, Glomerular Filtration Rate Stabilizes in Heart Transplant Patients on Chronic Cyclosporine. American Journal of Kidney Diseases, 1994, 24, 549-553.	1.9	32
565	Rare diseases: what's next?. Lancet, The, 2008, 371, 1978-1979.	11.9	32
566	Genetics and Genetic Testing in Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Seminars in Nephrology, 2010, 30, 395-408.	1.5	32
567	Preventing renal and cardiovascular risk by renal function assessment: insights from a cross-sectional study in low-income countries and the USA. BMJ Open, 2012, 2, e001357.	2.1	32
568	Rare Functional Variants in Complement Genes and Anti-FH Autoantibodies-Associated aHUS. Frontiers in Immunology, 2019, 10, 853.	4.8	32
569	Addition of cyclic angiotensin-(1-7) to angiotensin-converting enzyme inhibitor therapy has a positiveÂadd-on effect in experimental diabeticÂnephropathy. Kidney International, 2019, 96, 906-917.	5.3	32
570	Combined Treatment with Mycophenolate Mofetil and an Angiotensin II Receptor Antagonist Fully Protects from Chronic Rejection in a Rat Model of Renal Allograft. Journal of the American Society of Nephrology: JASN, 2001, 12, 1937-1946.	0.5	32
571	Glomerular Hyperfiltration and Urinary Prostaglandins in Type 1 Diabetes Mellitus. Diabetic Medicine, 1989, 6, 219-223.	2.5	31
572	Renal protective effect of angiotensin-converting enzyme inhibition in aging rats. American Journal of Medicine, 1992, 92, S60-S63.	1.4	31
573	Post-transplant renal artery stenosis: The hemodynamic response to revascularization. Kidney International, 2001, 60, 309-318.	5.3	31
574	ACE inhibition limits chronic injury of kidney transplant even with treatment started when lesions are established. Kidney International, 2003, 64, 2253-2261.	5.3	31
575	High-performance liquid chromatography with ultraviolet detection for therapeutic drug monitoring of everolimus. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2005, 816, 99-105.	2.4	31
576	Clinical update: immunosuppression minimisation. Lancet, The, 2007, 369, 1676-1678.	11.9	31

#	Article	IF	Citations
577	Translational Mini-Review Series on Complement Factor H: Therapies of renal diseases associated with complement factor H abnormalities: atypical haemolytic uraemic syndrome and membranoproliferative glomerulonephritis. Clinical and Experimental Immunology, 2008, 151, 199-209.	2.6	31
578	A German outbreak of haemolytic uraemic syndrome. Lancet, The, 2011, 378, 1057-1058.	11.9	31
579	Mesenchymal stromal cells to promote kidney transplantation tolerance. Current Opinion in Organ Transplantation, 2014, 19, 47-53.	1.5	31
580	Prevention programs for chronic kidney disease in low-income countries. Internal and Emergency Medicine, 2016, 11, 385-389.	2.2	31
581	Early and late scanning electron microscopy findingsÂin diabetic kidney disease. Scientific Reports, 2018, 8, 4909.	3.4	31
582	The European Rare Kidney Disease Registry (ERKReg): objectives, design and initial results. Orphanet Journal of Rare Diseases, 2021, 16, 251.	2.8	31
583	Neurological symptoms and coma associated with doxorubicin administration during chronic cyclosporin therapy. Lancet, The, 1992, 339, 1421.	11.9	30
584	Methylprednisolone normalizes superoxide anion production by polymorphs from patients with ANCA-positive vasculitides. Kidney International, 1993, 44, 215-220.	5.3	30
585	Toward novel antirejection strategies: In vivo immunosuppressive properties of CTLA4Ig. Kidney International, 1995, 47, 241-246.	5.3	30
586	B7â€“1 Is Not Induced in Podocytes of Human and Experimental Diabetic Nephropathy. Journal of the American Society of Nephrology: JASN, 2016, 27, 999-1005.	0.5	30
587	The role of B7-1 in proteinuria of glomerular origin. Nature Reviews Nephrology, 2018, 14, 589-596.	9.3	30
588	Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120. Clinical and Experimental Nephrology, 2018, 22, 299-308.	1.6	30
589	Renal Biopsy in Patients With Acute Renal Failure and Prolonged Bleeding Time: A Preliminary Report. American Journal of Kidney Diseases, 1985, 6, 397-399.	1.9	29
590	ACE inhibition prevents renal failure and death in uninephrectomized MWF/Ztm rats. Kidney International, 1995, 47, 1319-1326.	5.3	29
591	Sympathetic Overactivity in Hypertensive Patients with Chronic Renal Disease. New England Journal of Medicine, 1999, 340, 1360-1361.	29.6	29
592	Shear Stress-Induced Cytoskeleton Rearrangement Mediates NF-Î¹B-Dependent Endothelial Expression of ICAM-1. Microvascular Research, 2000, 60, 182-188.	2.5	29
593	Proteinuria in diabetic nephropathy: Treatment and evolution. Current Diabetes Reports, 2003, 3, 497-504.	4.3	29
594	Generic cyclosporine formulations: more open questions than answers. Transplant International, 2005, 18, 371-378.	1.7	29

#	Article	IF	Citations
595	Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. Experimental Dermatology, 2006, 15, 958-965.	2.9	29
596	Protein load impairs factor H binding promoting complement-dependent dysfunction of proximal tubular cells. Kidney International, 2009, 75, 1050-1059.	5.3	29
597	Outcome of Renal Transplantation from Very Old Donors. New England Journal of Medicine, 2009, 360, 1464-1465.	29.6	29
598	Impact of thePPAR-Î³2Pro12Ala Polymorphism and ACE Inhibitor Therapy on New-Onset Microalbuminuria in Type 2 Diabetes: Evidence From BENEDICT. Diabetes, 2009, 58, 2920-2929.	0.9	29
599	Inherited thrombotic thrombocytopenic purpura. Haematologica, 2009, 94, 166-170.	3.4	29
600	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes. Diabetes Care, 2010, 33, 1954-1956.	9.0	29
601	Prediction of the effect of atrasentan on renal and heart failure outcomes based on short-term changes in multiple risk markers. European Journal of Preventive Cardiology, 2016, 23, 758-768.	1.8	29
602	ACE and SGLT2 inhibitors: the future for non-diabetic and diabetic proteinuric renal disease. Current Opinion in Pharmacology, 2017, 33, 34-40.	3.5	29
603	Blood Pressure and Metabolic Effects of Acetyl-l-Carnitine in Type 2 Diabetes: DIABASI Randomized Controlled Trial. Journal of the Endocrine Society, 2018, 2, 420-436.	0.2	29
604	Engineered Kidney Tubules for Modeling Patient-Specific Diseases and Drug Discovery. EBioMedicine, 2018, 33, 253-268.	5.9	29
605	Therapeutic potential of stromal cells of non-renal or renal origin in experimental chronic kidney disease. Stem Cell Research and Therapy, 2018, 9, 220.	5.6	29
606	Recognition and management of community-acquired acute kidney injury in low-resource settings in the ISN 0by25 trial: A multi-country feasibility study. PLoS Medicine, 2021, 18, e1003408.	8.2	29
607	Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study. PLoS ONE, 2021, 16, e0261113.	2.5	29
608	Superimposed Nephritis: A Separate Entity Among Glomerular Diseases?. American Journal of Kidney Diseases, 1986, 7, 205-212.	1.9	28
609	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. Kidney International, 1990, 38, 447-458.	5.3	28
610	Cyclosporine enhances leukocyte adhesion to vascular endothelium under physiologic flow conditions. American Journal of Kidney Diseases, 1996, 28, 23-31.	1.9	28
611	PPARÂ2 P12A polymorphism and albuminuria in patients with type 2 diabetes: a meta-analysis of case-control studies. Nephrology Dialysis Transplantation, 2011, 26, 4011-4016.	0.7	28
612	C-Reactive Protein and Risk of ESRD: Results From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2016, 68, 873-881.	1.9	28

#	Article	IF	Citations
613	Catecholamine receptor binding in rat kidney: Effect of aging. Kidney International, 1988, 33, 1073-1077.	5.3	27
614	Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. Lancet, The, 1992, 339, 835-836.	11.9	27
615	Glomerular perm-selective function. Kidney International, 1994, 45, 398-402.	5.3	27
616	Complement factor H and hemolytic uremic syndrome. International Immunopharmacology, 2001, 1, 461-468.	3.8	27
617	Renal Transplantation: Can We Reduce Calcineurin Inhibitor/Stop Steroids? Evidence Based on Protocol Biopsy Findings. Journal of the American Society of Nephrology: JASN, 2003, 14, 755-766.	0.5	27
618	Pretransplant Donor Peripheral Blood Mononuclear Cells Infusion Induces Transplantation Tolerance by Generating Regulatory T Cells. Transplantation, 2005, 79, 1034-1039.	1.0	27
619	Immunophenotypic Analysis of Cellular Infiltrate of Renal Allograft Biopsies in Patients with Acute Rejection after Induction with Alemtuzumab (Campath-1H). Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 539-545.	4.3	27
620	Direct Reprogramming of Human Bone Marrow Stromal Cells into Functional Renal Cells Using Cell-free Extracts. Stem Cell Reports, 2015, 4, 685-698.	4.7	27
621	Albuminuria as early test for vascular disease. Lancet, The, 2005, 365, 556-557.	11.9	27
622	Endothelin Antagonists and Renal Protection. Journal of Cardiovascular Pharmacology, 2000, 35, S75-S78.	1.8	27
623	RENAL TRANSPLANTATION: SINGLE OR DUAL FOR DONORS AGING ???60 YEARS?. Transplantation, 2000, 69, 2000-2001.	1.0	27
624	Endothelin and eicosanoid synthesis in cultured mesangial cells. Kidney International, 1990, 37, 927-933.	5.3	26
625	Renal Prostacyclin Biosynthesis Is Reduced in Children With Hemolytic-Uremic Syndrome in the Context of Systemic Platelet Activation. American Journal of Kidney Diseases, 1992, 20, 144-149.	1.9	26
626	New insights into circulating cell-endothelium interactions and their significance for glomerular pathophysiology. American Journal of Kidney Diseases, 1995, 26, 541-548.	1.9	26
627	Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Kidney International, 1998, 54, 2146-2150.	5.3	26
628	Mitochondrial-dependent Autoimmunity in Membranous Nephropathy of IgG4-related Disease. EBioMedicine, 2015, 2, 456-466.	5.9	26
629	17Î²-Estradiol corrects hemostasis in uremic rats by limiting vascular expression of nitric oxide synthases. American Journal of Physiology - Renal Physiology, 2000, 279, F626-F635.	2.8	25
630	Subcutaneous xenotransplantation of bovine pancreatic islets. Biomaterials, 2005, 26, 5640-5647.	11.5	25

#	Article	IF	Citations
631	Monitoring Initial Response to Angiotensin-Converting Enzyme Inhibitorâ€“Based Regimens. Hypertension, 2010, 56, 533-539.	4.9	25
632	Both Darbepoetin Alfa and Carbamylated Erythropoietin Prevent Kidney Graft Dysfunction Due to Ischemia/Reperfusion in Rats. Transplantation, 2011, 92, 271-279.	1.0	25
633	Erythropoietin enhances immunostimulatory properties of immature dendritic cells. Clinical and Experimental Immunology, 2011, 165, 202-210.	2.6	25
634	ADAMTS13 Predicts Renal and Cardiovascular Events in Type 2 Diabetic Patients and Response to Therapy. Diabetes, 2013, 62, 3599-3609.	0.9	25
635	Treatment of Congenital Thrombotic Thrombocytopenic Purpura With Eculizumab. American Journal of Kidney Diseases, 2015, 66, 1067-1070.	1.9	25
636	BRAF Signaling Pathway Inhibition, Podocyte Injury, and Nephrotic Syndrome. American Journal of Kidney Diseases, 2017, 70, 145-150.	1.9	25
637	Moderate salt restriction with or without paricalcitol in type 2 diabetes and losartan-resistant macroalbuminuria (PROCEED): a randomised, double-blind, placebo-controlled, crossover trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 27-40.	11.1	25
638	Thymic Microchimerism Correlates with the Outcome of Tolerance-Inducing Protocols for Solid Organ Transplantation. Journal of the American Society of Nephrology: JASN, 2001, 12, 2815-2826.	0.5	25
639	Prostacyclin (PGI2) and bleeding time in uremic patients. Thrombosis Research, 1977, 11, 919-920.	1.7	24
640	Automatic Generation of Glomerular Capillary Topological Organization. Microvascular Research, 2001, 62, 346-354.	2.5	24
641	Preventing end-stage renal disease: the potential impact of screening and intervention in developing countries. Nephrology Dialysis Transplantation, 2003, 18, 858-859.	0.7	24
642	In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: Insights from the MY.S.S. Trial. Kidney International, 2004, 65, 1084-1090.	5.3	24
643	Independent clinical research in Europe. Lancet, The, 2004, 364, 1723-1726.	11.9	24
644	Pathophysiology of disease progression in proteinuric nephropathies. Kidney International, 2005, 67, S79-S82.	5.3	24
645	Dual Blockade of the Renin-Angiotensin System. Journal of the American Society of Nephrology: JASN, 2005, 16, S34-S38.	0.5	24
646	Severe early acute humoral rejection resulting in allograft loss in a renal transplant recipient with Campath-1H induction therapy. Nephrology Dialysis Transplantation, 2005, 20, 1741-1744.	0.7	24
647	Decision time for pancreatic islet-cell transplantation. Lancet, The, 2008, 371, 883-884.	11.9	24
648	A previously unrecognized role of C3a in proteinuric progressive nephropathy. Scientific Reports, 2016, 6, 28445.	3.4	24

#	Article	IF	Citations
649	Complement Activation Contributes to the Pathophysiology of Shiga Toxin-Associated Hemolytic Uremic Syndrome. Microorganisms, 2019, 7, 15.	3.6	24
650	Alteration of thyroid hormone signaling triggers the diabetes-induced pathological growth, remodeling, and dedifferentiation of podocytes. Journal of Clinical Investigation, 2019, 4, .	6.5	24
651	Cyclosporine-induced renal dysfunction in experimental animals and humans. Transplantation Reviews, 1991, 5, 63-80.	2.9	23
652	Research on renal endothelin in proteinuric nephropathies dictates novel strategies to prevent progression. Current Opinion in Nephrology and Hypertension, 2001, 10, 1-6.	2.0	23
653	Effect of high dose ramipril with or without indomethacin on glomerular selectivity. Kidney International, 2002, 62, 1010-1019.	5.3	23
654	Albumin concentration in the Bowman's capsule: Multiphoton microscopy vs micropuncture technique. Kidney International, 2007, 72, 1410-1411.	5.3	23
655	Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies. Journal of Hypertension, 2007, 25, 871-876.	0.5	23
656	Immunomodulatory effects of mesenchymal stromal cells in solid organ transplantation. Current Opinion in Organ Transplantation, 2010, 15, 731-737.	1.5	23
657	Circulating Anti-PLA2R Autoantibodies to Monitor Immunological Activity in Membranous Nephropathy. Journal of the American Society of Nephrology: JASN, 2011, 22, 1400-1402.	0.5	23
658	Mortality landscape in the Global Burden of Diseases, Injuries and Risk Factors Study. European Journal of Internal Medicine, 2014, 25, 1-5.	2.2	23
659	Mesenchymal stromal cells to control donor-specific memory T cells in solid organ transplantation. Current Opinion in Organ Transplantation, 2015, 20, 79-85.	1.5	23
660	Nephrology researchâ€"the past, present and future. Nature Reviews Nephrology, 2015, 11, 677-687.	9.3	23
661	Empagliflozin protects glomerular endothelial cell architecture in experimental diabetes through the <scp>VEGFâ€A</scp>/caveolinâ€1/<scp>PV</scp>â€1 signaling pathway. Journal of Pathology, 2022, 256, 468-479.	4.4	23
662	Skin fibroblasts from a patient with Glanzmann's Thrombasthenia do not induce fibrin clot retraction. Thrombosis Research, 1977, 10, 173-174.	1.7	22
663	RENAL BIOPSY IN PATIENTS WITH ACUTE RENAL FAILURE AND PROLONGED BLEEDING TIME. Lancet, The, 1984, 324, 978-979.	11.9	22
664	Angiotensin-Converting Enzyme Inhibition Ameliorates the Defect in Glomerular Size Selectivity in Hyponatremic Hypertensive Syndrome. American Journal of Kidney Diseases, 1989, 14, 170-177.	1.9	22
665	CO-PARTICIPATION OF THROMBOXANE A2 AND LEUKOTRIENE C4 AND D4 IN MEDIATING CYCLOSPORINE-INDUCED ACUTE RENAL FAILURE. Transplantation, 1991, 52, 873-878.	1.0	22
666	Methylprednisolone dosage effects on peripheral lymphocyte subpopulations and eicosanoid synthesis. Kidney International, 1992, 42, 981-990.	5.3	22

#	Article	IF	Citations
667	Glucose-induced changes in renal haemodynamics in proteinuric Type 1 (insulin-dependent) diabetic patients: inhibition by acetylsalicilic acid infusion. Diabetologia, 1993, 36, 622-627.	6.4	22
668	Urinary excretion of platelet activating factor in patients with immune-mediated glomerulonephritis. Kidney International, 1993, 43, 426-429.	5.3	22
669	Î±1-antitrypsin therapy in a case of thrombotic thrombocytopenic purpura. Lancet, The, 1995, 345, 224-225.	11.9	22
670	Acceleration of Recovery in Acute Renal Failure: From Cellular Mechanisms of Tubular Repair to Innovative Targeted Therapies. Renal Failure, 1996, 18, 377-388.	1.9	22
671	Routine renin-angiotensin system blockade in renal transplantation?. Current Opinion in Nephrology and Hypertension, 2002, 11, 1-10.	2.0	22
672	DnIKK2-Transfected Dendritic Cells Induce a Novel Population of Inducible Nitric Oxide Synthase???Expressing CD4+CD25??? Cells with Tolerogenic Properties. Transplantation, 2007, 83, 474-484.	1.0	22
673	Sirolimus to replace calcineurin inhibitors? Too early yet. Lancet, The, 2009, 373, 1235-1236.	11.9	22
674	Systems biology to battle vascular disease. Nephrology Dialysis Transplantation, 2010, 25, 1019-1022.	0.7	22
675	Rabbit anti-rat thymocyte immunoglobulin preserves renal function during ischemia/reperfusion injury in rat kidney transplantation. Transplant International, 2011, 24, 829-838.	1.7	22
676	Acute kidney injury in low-income and middle-income countries: no longer a death sentence. The Lancet Global Health, 2016, 4, e216-e217.	6.2	22
677	Liver transplantation for aHUS: still needed in the eculizumab era?. Pediatric Nephrology, 2016, 31, 759-768.	1.7	22
678	The effects of atrasentan on urinary metabolites in patients with type 2 diabetes and nephropathy. Diabetes, Obesity and Metabolism, 2017, 19, 749-753.	4.5	22
679	Kidney transplant tolerance associated with remote autologous mesenchymal stromal cell administration. Stem Cells Translational Medicine, 2020, 9, 427-432.	3.4	22
680	Third-party bone marrowâ€“derived mesenchymal stromal cell infusion before liver transplantation: A randomized controlled trial. American Journal of Transplantation, 2021, 21, 2795-2809.	4.7	22
681	RECOVERY OF BLOOD MONONUCLEAR CELL CALCINEURIN ACTIVITY SEGREGATES TWO POPULATIONS OF RENAL TRANSPLANT PATIENTS WITH DIFFERENT SENSITIVITIES TO CYCLOSPORINE INHIBITION. Transplantation, 1996, 61, 1526-1531.	1.0	22
682	Glomerular response to hyperglycemia in human diabetic nephropathy. American Journal of Physiology - Renal Physiology, 1990, 259, F545-F552.	2.8	21
683	Defective Platelet Aggregation in Response to Platelet-Activating Factor in Uremia Associated With Low Platelet Thromboxane A2 Generation. American Journal of Kidney Diseases, 1992, 19, 318-325.	1.9	21
684	Failure to predict cyclosporine area under the curve using a limited sampling strategy. Kidney International, 1993, 44, 436-439.	5.3	21

#	Article	IF	Citations
685	Lessons from the Di Bella affair. Lancet, The, 1999, 353, 1289-1290.	11.9	21
686	Preventing end-stage renal disease: The potential impact of screening and intervention in developing countries. Kidney International, 2003, 63, 1948-1950.	5.3	21
687	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports, 2007, 9, 430-436.	3.3	21
688	Cost-effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: influence of the ACE insertion/deletion polymorphism. Pharmacogenetics and Genomics, 2009, 19, 695-703.	1.5	21
689	Enzyme Replacement Therapy and Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 371-378.	4.3	21
690	Hemoglobin Stability in Patients With Anemia, CKD, and Type 2 Diabetes: An Analysis of the TREAT (Trial) Tj ETQq0 0 0 rgBT /Overlock 10 Diseases, 2013, 61, 238-246.	1.9	21
691	Baseline characteristics in the Bardoxolone methyl EvAluation in patients with Chronic kidney disease and type 2 diabetes mellitus: the Occurrence of renal eveNts (BEACON) trial. Nephrology Dialysis Transplantation, 2013, 28, 2841-2850.	0.7	21
692	Genetics of Immune-Mediated Glomerular Diseases: Focus on Complement. Seminars in Nephrology, 2017, 37, 447-463.	1.5	21
693	Relationships among natriuresis, atrial natriuretic peptide and insulin in insulin-dependent diabetes. Kidney International, 1992, 41, 813-821.	5.3	20
694	Modulating the profit motive to meet needs of the less-developed world. Lancet, The, 2001, 358, 1638-1641.	11.9	20
695	Kidney Failure Stabilizes after a Two-Decade Increase: Impact on Global (Renal and Cardiovascular) Health. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 146-150.	4.3	20
696	Which antihypertensive drugs are the most nephroprotective and why?. Expert Opinion on Pharmacotherapy, 2010, 11, 2651-2663.	1.9	20
697	Time-Domain and Spectral-Domain Optical Coherence Tomography of Retinal Nerve Fiber Layer in MS Patients and Healthy Controls. Journal of Ophthalmology, 2012, 2012, 1-7.	1.3	20
698	Acute kidney injury: more awareness needed, globally. Lancet, The, 2015, 386, 1425-1427.	11.9	20
699	The Role of Angiotensin II in Parietal Epithelial Cell Proliferation and Crescent Formation in Glomerular Diseases. American Journal of Pathology, 2017, 187, 2441-2450.	4.0	20
700	Xenogeneic Serum Promotes Leukocyte-Endothelium Interaction under Flow through Two Temporally Distinct Pathways. Journal of the American Society of Nephrology: JASN, 1999, 10, 2197-2207.	0.5	20
701	Slowing the Progression of Diabetic Nephropathy. New England Journal of Medicine, 1993, 329, 1496-1497.	29.6	19
702	Nonimmunosuppressive therapy of membranous nephropathy. Seminars in Nephrology, 2003, 23, 333-339.	1.5	19

#	Article	IF	Citations
703	Assessing Renal Function by GFR Prediction Equations in Kidney Transplantation. American Journal of Transplantation, 2005, 5, 1175-1176.	4.7	19
704	Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management?. Nature Clinical Practice Nephrology, 2005, 1, 2-3.	0.9	19
705	Proteinuria and its consequences in renal disease. Acta Paediatrica, International Journal of Paediatrics, 2003, 92, 9-13.	1.5	19
706	Intermediate Volume on Computed Tomography Imaging Defines a Fibrotic Compartment that Predicts Glomerular Filtration Rate Decline in Autosomal Dominant Polycystic Kidney Disease Patients. American Journal of Pathology, 2011, 179, 619-627.	4.0	19
707	Discordant phenotype in monozygotic twins with renal coloboma syndrome and a PAX2 mutation. Pediatric Nephrology, 2012, 27, 1989-1993.	1.7	19
708	Eliminating Treatable Deaths Due to Acute Kidney Injury in Resourceâ€Poor Settings. Seminars in Dialysis, 2015, 28, 193-197.	1.3	19
709	Combined neprilysin and RAS inhibition for the failing heart: straining the kidney to help the heart?. European Journal of Heart Failure, 2015, 17, 468-471.	7.3	19
710	Treatment of Anemia With Darbepoetin Prior to Dialysis Initiation and Clinical Outcomes: Analyses From the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). American Journal of Kidney Diseases, 2019, 73, 309-315.	1.9	19
711	Transplantation-Induced Ischemia-Reperfusion Injury Modulates Antigen Presentation by Donor Renal CD11c+F4/80+ Macrophages through IL-1R8 Regulation. Journal of the American Society of Nephrology: JASN, 2020, 31, 517-531.	0.5	19
712	Mesenchymal Stromal Cell Therapy in Solid Organ Transplantation. Frontiers in Immunology, 2020, 11, 618243.	4.8	19
713	Hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infection in acquired immunodeficiency syndrome [letter]. Blood, 1990, 75, 2465-2465.	1.4	18
714	The diagnosis of renal involvement in non-insulin-dependent diabetes mellitus. Current Opinion in Nephrology and Hypertension, 1997, 6, 141-145.	2.0	18
715	Endothelin receptor antagonists: which are the therapeutic perspectives in renal diseases?. Nephrology Dialysis Transplantation, 1998, 13, 5-7.	0.7	18
716	Renoprotective Therapy in Patients With Nondiabetic Nephropathies. Drugs, 2001, 61, 733-745.	10.8	18
717	The future of renoprotection. Kidney International, 2005, 68, S95-S101.	5.3	18
718	Latest treatment strategies for membranous nephropathy. Expert Opinion on Pharmacotherapy, 2007, 8, 3159-3171.	1.9	18
719	Primer: strategies for identifying genes involved in renal disease. Nature Clinical Practice Nephrology, 2008, 4, 265-276.	0.9	18
720	Aldosterone and progression of kidney disease. Therapeutic Advances in Cardiovascular Disease, 2009, 3, 133-143.	2.1	18

#	Article	IF	Citations
721	Rituximab for membranous nephropathy and immune disease: less might be enough. Nature Clinical Practice Nephrology, 2009, 5, 76-77.	0.9	18
722	Antihypertensive effects of double the maximum dose of valsartan in Africanâ€“American patients with type 2 diabetes mellitus and albuminuria. Journal of Hypertension, 2010, 28, 186-193.	0.5	18
723	Nephrology in developing countries: the ISN's story. Lancet, The, 2014, 383, 1271-1272.	11.9	18
724	The Cost of Patients with Chronic Kidney Failure Before Dialysis: Results from the IRIDE Observational Study. PharmacoEconomics - Open, 2018, 2, 459-467.	1.8	18
725	Measles Virus Infection Fosters Dendritic Cell Motility in a 3D Environment to Enhance Transmission to Target Cells in the Respiratory Epithelium. Frontiers in Immunology, 2019, 10, 1294.	4.8	18
726	Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatment. Nephrology Dialysis Transplantation, 2023, 38, 283-290.	0.7	18
727	Fresh lemon juice supplementation for the prevention of recurrent stones in calcium oxalate nephrolithiasis: A pragmatic, prospective, randomised, open, blinded endpoint (PROBE) trial. EClinicalMedicine, 2022, 43, 101227.	7.0	18
728	A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2). Frontiers in Medicine, 2022, 9, 785785.	2.6	18
729	Human renal cortex generates prostacyclin-like activity. Thrombosis Research, 1978, 12, 363-366.	1.7	17
730	In vivo platelet activation with in vitro hyperaggregability to arachidonic acid in renal allograft recipients. Kidney International, 1983, 23, 506-513.	5.3	17
731	Increased urinary excretion of platelet activating factor in mice with lupus nephritis. Life Sciences, 1991, 48, 1429-1437.	4.3	17
732	Prevention of progression and remission/regression strategies for chronic renal diseases: Can we do better now than five years ago?. Kidney International, 2005, 68, S21-S24.	5.3	17
733	Comparison of different cyclosporine immunoassays to monitor C0 and C2 blood levels from kidney transplant recipients: Not simply overestimation. Clinica Chimica Acta, 2005, 355, 153-164.	1.6	17
734	Thrice-Weekly In-Center Nocturnal Hemodialysis: An Effective Strategy to Optimize Chronic Dialysis Therapy. International Journal of Artificial Organs, 2009, 32, 12-19.	1.4	17
735	Non-immune interventions to protect kidney allografts in the long term. Kidney International, 2010, 78, S71-S75.	5.3	17
736	Renal Primordia Activate Kidney Regenerative Events in a Rat Model of Progressive Renal Disease. PLoS ONE, 2015, 10, e0120235.	2.5	17
737	Physiological and pathophysiological implications of PGE2 and the PGE2 synthases in the kidney. Prostaglandins and Other Lipid Mediators, 2018, 134, 1-6.	2.0	17
738	Toward longitudinal studies of hemodynamically induced vessel wall remodeling. International Journal of Artificial Organs, 2018, 41, 714-722.	1.4	17

#	Article	IF	Citations
739	Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial. American Journal of Kidney Diseases, 2019, 74, 338-350.	1.9	17
740	Albuminuria as a risk factor for mild cognitive impairment and dementiaâ€"what is the evidence?. Nephrology Dialysis Transplantation, 2021, 37, ii55-ii62.	0.7	17
741	Acquired transplant tolerance. International Journal of Clinical and Laboratory Research, 1997, 27, 165-177.	0.9	16
742	Angiotensin II receptor antagonists and treatment of hypertension and renal disease. Current Opinion in Nephrology and Hypertension, 1998, 7, 571-578.	2.0	16
743	Losartan in diabetic nephropathy. Expert Review of Cardiovascular Therapy, 2004, 2, 473-483.	1.5	16
744	Lipid oxidative stress and the anti-inflammatory properties of statins and ACE inhibitors. , 2005, 15, 71-76.		16
745	Successes and Disappointments with Clinical Islet Transplantation. Advances in Experimental Medicine and Biology, 2010, 654, 749-769.	9.0	16
746	Effect of Trandolapril on Regression of Retinopathy in Hypertensive Patients with Type 2 Diabetes: A Prespecified Analysis of the Benedict Trial. Journal of Ophthalmology, 2010, 2010, 1-9.	1.3	16
747	Non-muscle myosins and the podocyte. CKJ: Clinical Kidney Journal, 2012, 5, 94-101.	2.7	16
748	Sirtuin3 Dysfunction Is the Key Determinant of Skeletal Muscle Insulin Resistance by Angiotensin II. PLoS ONE, 2015, 10, e0127172.	2.5	16
749	ESRD After Heart Failure, Myocardial Infarction, or Stroke in TypeÂ2 Diabetic Patients With CKD. American Journal of Kidney Diseases, 2017, 70, 522-531.	1.9	16
750	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. Diabetes, Obesity and Metabolism, 2019, 21, 1177-1190.	4.5	16
751	Urinary proteome signature of Renal Cysts and Diabetes syndrome in children. Scientific Reports, 2019, 9, 2225.	3.4	16
752	Myasthenia Gravis, Thrombocytopenia and HLA Antigens. Annals of Internal Medicine, 1977, 87, 250.	10.0	15
753	PROSTACYCLIN DEFICIENCY IN THROMBOTIC MICROANGIOPATHY. Lancet, The, 1981, 318, 1422-1423.	11.9	15
754	Low-Protein Diet and Glomerular Size-Selective Function in Membranous Glomerulopathy. American Journal of Kidney Diseases, 1991, 17, 317-322.	1.9	15
755	Heparin-induced thrombocytopenia--background and implications for haemodialysis. Nephrology Dialysis Transplantation, 1996, 11, 2120-2122.	0.7	15
756	Meeting report on the Bellagio Conference â€˜prevention of vascular diseases in the emerging world: An approach to global health equityâ€™. Kidney International, 2006, 70, 1397-1402.	5.3	15

#	Article	IF	Citations
757	What not to learn from a meta-analysis. Nature Reviews Nephrology, 2009, 5, 186-188.	9.3	15
758	Spironolactone Plus Full-Dose ACE Inhibition in Patients with Idiopathic Membranous Nephropathy and Nephrotic Syndrome: Does It Really Work?. Pharmaceuticals, 2010, 3, 1-9.	3.8	15
759	THE DIABETIC CKD PATIENTâ€"A MAJOR CARDIOVASCULAR CHALLENGE. Journal of Renal Care, 2010, 36, 34-46.	1.2	15
760	Spatial Correlation and Ergodic Capacity of MIMO Channel in Reverberation Chamber. International Journal of Antennas and Propagation, 2012, 2012, 1-7.	1.3	15
761	Management of chronic kidney disease and its risk factors in eastern Nepal. The Lancet Global Health, 2014, 2, e506-e507.	6.2	15
762	Bergamo and Covid-19: How the Dark Can Turn to Light. Frontiers in Medicine, 2021, 8, 609440.	2.6	15
763	SARS-CoV-2 and the spike protein in endotheliopathy. Trends in Microbiology, 2024, 32, 53-67.	7.6	15
764	EVIDENCE OF THE CENTRAL ROLE OF THE THYMUS IN THE INDUCTION OF DONOR-SPECIFIC UNRESPON-SIVENESS TO A RENAL ALLOGRAFT. Transplantation, 1992, 54, 943-944.	1.0	14
765	A novel interpretation of the role of von Willebrand factor in thrombotic microangiopathies based on platelet adhesion studies at high shear rate flow. American Journal of Kidney Diseases, 2000, 36, 695-702.	1.9	14
766	Cyclosporine Formulation and Kaposiâ€™s Sarcoma after Renal Transplantation. Transplantation, 2005, 80, 743-748.	1.0	14
767	Activation of porcine endothelium in response to xenogeneic serum causes thrombosis independently of platelet activation. Xenotransplantation, 2005, 12, 110-120.	3.0	14
768	Mycophenolate Mofetil Versus Azathioprine in Organ Transplantation. American Journal of Transplantation, 2009, 9, 2856-2857.	4.7	14
769	Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice. Gene Therapy, 2009, 16, 1373-1379.	4.6	14
770	Effect of ACE inhibition on glomerular permselectivity and tubular albumin concentration in the renal ablation model. American Journal of Physiology - Renal Physiology, 2011, 300, F1291-F1300.	2.8	14
771	Clinical use of computational modeling for surgical planning of arteriovenous fistula for hemodialysis. BMC Medical Informatics and Decision Making, 2017, 17, 26.	3.0	14
772	Effect of Timing and Complement Receptor Antagonism on Intragraft Recruitment and Protolerogenic Effects of Mesenchymal Stromal Cells in Murine Kidney Transplantation. Transplantation, 2019, 103, 1121-1130.	1.0	14
773	Left ventricular dysfunction in ADPKD and effects of octreotide-LAR: A cross-sectional and longitudinal substudy of the ALADIN trial. International Journal of Cardiology, 2019, 275, 145-151.	1.6	14
774	Disaster medicine and response: Optimizing life-saving potential. American Journal of Disaster Medicine, 2018, 13, 253-264.	0.3	14

#	Article	IF	Citations
775	Safety and Preliminary Efficacy of Mesenchymal Stromal Cell (ORBCEL-M) Therapy in Diabetic Kidney Disease: A Randomized Clinical Trial (NEPHSTROM). Journal of the American Society of Nephrology: JASN, 2023, 34, 1733-1751.	0.5	14
776	ABNORMAL TISSUE REPAIR IN GLANZMANN'S THROMBASTHENIA. Lancet, The, 1977, 309, 374-375.	11.9	13
777	High-performance liquid chromatographic determination of iothalamic acid in human plasma and urine. Biomedical Applications, 1991, 570, 435-440.	1.7	13
778	A unifying hypothesis for renal scarring linking protein trafficking to the different mediators of injury. Nephrology Dialysis Transplantation, 2000, 15, 58-60.	0.7	13
779	Combining lisinopril and L-arginine slows disease progression and reduces endothelin-1 in passive Heymann nephritis. Kidney International, 2003, 64, 857-863.	5.3	13
780	Review: Potential protective effects of telmisartan on renal function deterioration. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2006, 7, 185-191.	1.6	13
781	Do mTOR inhibitors still have a future in ADPKD?. Nature Reviews Nephrology, 2010, 6, 696-698.	9.3	13
782	ADAMTS13 Secretion and Residual Activity among Patients with Congenital Thrombotic Thrombocytopenic Purpura with and without Renal Impairment. Clinical Journal of the American Society of Nephrology: CJASN, 2015, 10, 2002-2012.	4.3	13
783	Kidney Transplantation in Patients With Atypical Hemolytic Uremic Syndrome: A Therapeutic Dilemma (or Not)?. American Journal of Kidney Diseases, 2017, 70, 754-757.	1.9	13
784	Mesenchymal stromal cells in kidney transplantation. Current Opinion in Nephrology and Hypertension, 2019, 28, 40-46.	2.0	13
785	Submaximal exercise blood pressure and cardiovascular structure in adolescence. International Journal of Cardiology, 2019, 275, 152-157.	1.6	13
786	Glomerular size selectivity in nephrotic rats exposed to diets with different protein content. American Journal of Physiology - Renal Physiology, 1987, 253, F318-F327.	2.8	12
787	Xenogeneic human serum promotes leukocyte adhesion to porcine endothelium under flow conditions, possibly through the activation of the transcription factor NFâ€ºB. Xenotransplantation, 1998, 5, 57-60.	3.0	12
788	Repairing renal lesions: Will VEGF be the builder?. Kidney International, 2000, 58, 2594-2595.	5.3	12
789	ACE inhibitors and AT1 receptor antagonists: Is two better than one?. Kidney International, 2002, 61, 1545-1547.	5.3	12
790	The potential of endothelin antagonism as a therapeutic approach. Expert Opinion on Investigational Drugs, 2004, 13, 1419-1435.	4.0	12
791	Increased angiotensin-receptor blocking is not the first option. Nature Reviews Nephrology, 2009, 5, 367-368.	9.3	12
792	The ERA-EDTA Working Group on inherited kidney disorders. Nephrology Dialysis Transplantation, 2012, 27, 67-69.	0.7	12

#	Article	IF	Citations
793	Mapping KT interventions to barriers and facilitators. , 2013, , 137-149.		12
794	Building a network of ADPKD reference centres across Europe: the EuroCYST initiative. Nephrology Dialysis Transplantation, 2014, 29, iv26-iv32.	0.7	12
795	Inhibiting angiotensin-converting enzyme promotes renal repair by modulating progenitor cell activation. Pharmacological Research, 2016, 108, 16-22.	7.1	12
796	Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase. Journal of Biological Chemistry, 2016, 291, 8214-8230a.	3.4	12
797	Achieving remission of proteinuria in childhood CKD. Pediatric Nephrology, 2017, 32, 321-330.	1.7	12
798	Prognosis and determinants of serum PTH changes over time in 1-5 CKD stage patients followed in tertiary care. PLoS ONE, 2018, 13, e0202417.	2.5	12
799	CFH and CFHR Copy Number Variations in C3 Glomerulopathy and Immune Complex-Mediated Membranoproliferative Glomerulonephritis. Frontiers in Genetics, 2021, 12, 670727.	2.3	12
800	Renal metabolism and urinary excretion of platelet-activating factor in the rat.. Journal of Biological Chemistry, 1990, 265, 19414-19419.	3.4	12
801	CTLA4Ig ALONE OR IN COMBINATION WITH LOW-DOSE CYCLOSPORINE FAILS TO REVERSE ACUTE REJECTION OF RENAL ALLOGRAFT IN THE RAT. Transplantation, 1996, 61, 1320-1322.	1.0	12
802	Colchicine allows prolonged survival of highly reactive renal allograft in the rat.. Journal of the American Society of Nephrology: JASN, 1993, 4, 1294-1299.	0.5	12
803	Neuropeptide Y as a risk factor for cardiorenal disease and cognitive dysfunction in chronic kidney disease: translational opportunities and challenges. Nephrology Dialysis Transplantation, 2021, 37, ii14-ii23.	0.7	12
804	Post-translational modifications by SIRT3 de-2-hydroxyisobutyrylase activity regulate glycolysis and enable nephrogenesis. Scientific Reports, 2021, 11, 23580.	3.4	12
805	Heparin for Hemodialysis: Practical Guidelines for Administration and Monitoring. International Journal of Artificial Organs, 1984, 7, 269-274.	1.4	11
806	Preliminary report: renal thromboxane A2 synthesis in children with frequent relapsing nephrotic syndrome. Lancet, The, 1990, 336, 533-534.	11.9	11
807	Supernatant of endothelial cells exposed to laminar flow inhibits mesangial cell proliferation. American Journal of Physiology - Cell Physiology, 1993, 264, C1080-C1083.	4.5	11
808	The renoprotective potential of endothelin receptor antagonists. Expert Opinion on Therapeutic Patents, 1997, 7, 139-149.	5.1	11
809	Renoprotective effect of ACE inhibitors: Dissecting the molecular clues and expanding the blood pressure goal. American Journal of Kidney Diseases, 1999, 34, 951-954.	1.9	11
810	Optimization of cyclosporine therapy in the neoral era: abbreviated AUC, single blood sampling?. Transplantation Proceedings, 2001, 33, 3117-3119.	0.6	11

#	Article	IF	Citations
811	Novel mechanism(s) implicated in tubular albumin reabsorption and handling. American Journal of Kidney Diseases, 2001, 38, 196-200.	1.9	11
812	Investigational drugs for diabetic nephropathy. Expert Opinion on Investigational Drugs, 2008, 17, 1487-1500.	4.0	11
813	Prevalence of Hypertension and Diabetes and Coexistence of Chronic Kidney Disease and Cardiovascular Risk in the Population of the Republic of Moldova. International Journal of Hypertension, 2012, 2012, 1-8.	1.3	11
814	Do attributes of persons with chronic kidney disease differ in low-income and middle-income countries compared with high-income countries? Evidence from population-based data in six countries. BMJ Global Health, 2017, 2, e000453.	5.4	11
815	Terminal complement effectors in atypical hemolytic uremic syndrome: C5a, C5b-9, or a bitÂof both?. Kidney International, 2019, 96, 13-15.	5.3	11
816	Impact of a Complement Factor H Gene Variant on Renal Dysfunction, Cardiovascular Events, and Response to ACE Inhibitor Therapy in Type 2 Diabetes. Frontiers in Genetics, 2019, 10, 681.	2.3	11
817	Long-term kidney and systemic effects of calorie restriction in overweight or obese type 2 diabetic patients (C.Re.S.O. 2 randomized controlled trial). Diabetes Research and Clinical Practice, 2022, 185, 109804.	2.8	11
818	The Lupus Anticoagulant. Experimental Biology and Medicine, 1984, 176, 337-341.	2.4	10
819	Studies by conventional and â€œlow denaturingâ€•isoelectric focusing on albumin microheterogeneity under normal conditions and in experimental nephrosis. Electrophoresis, 1987, 8, 215-220.	2.8	10
820	Influence of Antacid Administrations on Aspirin Absorption in Patients With Chronic Renal Failure on Maintenance Hemodialysis. American Journal of Kidney Diseases, 1988, 11, 338-342.	1.9	10
821	Pretreatment blood pressure reliably predicts progression of chronic nephropathies. Kidney International, 2000, 58, 2093-2101.	5.3	10
822	Impediments to successful gene transfer to the kidney in the context of transplantation and how to overcome them. Kidney International, 2002, 61, S115-S119.	5.3	10
823	Predicting end-stage renal disease: Bayesian perspective of information transfer in the clinical decision-making process at the individual level. Kidney International, 2003, 63, 1924-1933.	5.3	10
824	Inhibition of TGF-Î² expression: A novel role for thiazolidinediones to implement renoprotection in diabetes. Kidney International, 2007, 72, 1419-1421.	5.3	10
825	Pharmacokinetic/Pharmacodynamic Drug Interaction Between Rosiglitazone and Mycophenolate Mofetil in Kidney Transplantation: A Case Report. Transplantation, 2008, 85, 921-922.	1.0	10
826	Time to rethink immunosuppression by mTOR inhibitors?. Nature Reviews Nephrology, 2009, 5, 611-612.	9.3	10
827	A First Step toward a New Approach to Treating Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 86-88.	29.6	10
828	A preclinical overview of emerging therapeutic targets for glomerular diseases. Expert Opinion on Therapeutic Targets, 2019, 23, 593-606.	3.3	10

#	Article	IF	Citations
829	Role of ultrastructural determinants of glomerular permeability in ultrafiltration function loss. Journal of Clinical Investigation, 2020, 5, .	6.5	10
830	Factor VIII--related protein on vascular intima of patients with chronic renal failure and prolonged bleeding times.. The BMJ, 1978, 1, 70-72.	0.6	9
831	Prevalence and Significance of Hypertension in Systemic Lupus Erythematosus. American Journal of Kidney Diseases, 1993, 21, 58-60.	1.9	9
832	Dissociation between antiproteinuric and antihypertensive effect of angiotensin converting enzyme inhibitors in rats. American Journal of Physiology - Renal Physiology, 1994, 267, F1034-F1044.	2.8	9
833	Novel strategies to retard renal disease progression: combining ACE inhibition with endothelin receptor blocking?. Nephrology Dialysis Transplantation, 1998, 13, 2734-2738.	0.7	9
834	One or two marginal organs for kidney transplantation?. Transplantation Proceedings, 2002, 34, 3091-3096.	0.6	9
835	Emerging drugs for diabetic nephropathy. Expert Opinion on Emerging Drugs, 2005, 10, 747-771.	2.4	9
836	Modeling of a parallel hybrid power audio amplifier. Industrial Electronics Society (IECON), Annual Conference of IEEE, 2006, , .	0.0	9
837	Treating the kidney to cure the heart. Kidney International, 2008, 74, S2-S3.	5.3	9
838	Embryonic Stem Cells, Derived Either after In Vitro Fertilization or Nuclear Transfer, Prolong Survival of Semiallogeneic Heart Transplants. Journal of Immunology, 2011, 186, 4164-4174.	0.8	9
839	E. coli O104:H4 German outbreak: a missed opportunity. Nature Reviews Nephrology, 2012, 8, 558-560.	9.3	9
840	Perioperative Minimal Induction Therapy: A Further Step toward More Effective Immunosuppression in Transplantation. Journal of Transplantation, 2012, 2012, 1-7.	0.5	9
841	An Unanticipated Role for Survivin in Organ Transplant Damage. American Journal of Transplantation, 2014, 14, 1046-1060.	4.7	9
842	ADAMTS13 Deficiency Shortens the Life Span of Mice With Experimental Diabetes. Diabetes, 2018, 67, 2069-2083.	0.9	9
843	More about Factor H Autoantibodies in Membranous Nephropathy. New England Journal of Medicine, 2019, 381, 1590-1592.	29.6	9
844	Molecular Studies and an ex vivo Complement Assay on Endothelium Highlight the Genetic Complexity of Atypical Hemolytic Uremic Syndrome: The Case of a Pedigree With a Null CD46 Variant. Frontiers in Medicine, 2020, 7, 579418.	2.6	9
845	Editorial: Ozone as a Driver of Lung Inflammation and Innate Immunity and as a Model for Lung Disease. Frontiers in Immunology, 2021, 12, 714161.	4.8	9
846	Development of a mass spectrometric method to quantitate platelet activating factor in mouse urine.. Journal of Lipid Research, 1989, 30, 1977-1981.	4.1	9

#	Article	IF	Citations
847	Metabolism of arachidonic acid in isolated glomeruli from pig kidney. Lipids and Lipid Metabolism, 1988, 961, 110-121.	2.3	8
848	Hyperparathyroidism Does Not Influence the Abnormal Primary Haemostasis in Patients with Chronic Renal Failure. Nephrology Dialysis Transplantation, 1989, 4, 971-974.	0.7	8
849	Abnormalities in arachidonic acid metabolites in nephrotoxic glomerular injury. Toxicology Letters, 1989, 46, 65-75.	1.3	8
850	Morphometrical Analysis of Glomerular Changes Induced by Cyclosporine in the Rat. American Journal of Kidney Diseases, 1991, 17, 537-543.	1.9	8
851	Idiopathic membranous nephropathy. Lancet, The, 1993, 342, 1277-1280.	11.9	8
852	The role of vasoactive molecules of endothelial origin in the pathophysiology of normal pregnancy and pregnancy-induced hypertension. Current Opinion in Nephrology and Hypertension, 1996, 5, 347-352.	2.0	8
853	Prognosis of diabetic nephropathy: how to improve the outcome. Diabetes Research and Clinical Practice, 1998, 39, S49-S53.	2.8	8
854	Transplant tolerance: will genes protect the graft?. Lancet, The, 1998, 351, 1749-1751.	11.9	8
855	IgA nephropathy: A stem cell disease?. Kidney International, 1999, 56, 1964-1966.	5.3	8
856	Hyperhomocysteinemia and Increased Risk of Retinopathy: A cross-sectional, case-control study in patients with type 2 diabetes. Diabetes Care, 2002, 25, 2361-2361.	9.0	8
857	Is Regression of Chronic Nephropathies a Therapeutic Target?. Journal of the American Society of Nephrology: JASN, 2005, 16, 840-842.	0.5	8
858	Blood Cyclosporine Level Soon After Kidney Transplantation is a Major Determinant of Rejection: Insights From the Mycophenolate Steroid-Sparing Trial. Transplantation Proceedings, 2005, 37, 2037-2040.	0.6	8
859	Low-Dose Rituximab for Posttransplant Recurrent Membranous Nephropathy. American Journal of Transplantation, 2010, 10, 1336.	4.7	8
860	Idiopathic membranous nephropathy: back to the future?. Lancet, The, 2013, 381, 706-708.	11.9	8
861	Chronic kidney disease in sub-Saharan Africa: a public health priority. The Lancet Global Health, 2014, 2, e124-e125.	6.2	8
862	Determining the Optimal Protocol for Measuring an Albuminuria Class Transition in Clinical Trials in Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2016, 27, 3405-3412.	0.5	8
863	The establishment and validation of novel therapeutic targets to retard progression of chronic kidney disease. Kidney International Supplements, 2017, 7, 130-137.	12.5	8
864	Atypical hemolytic uremic syndrome associated with a factor B genetic variant and fluid-phase complement activation: an exception to the rule?. Kidney International, 2020, 98, 1084-1087.	5.3	8

#	Article	IF	Citations
865	Mycophenolate mofetil versus azathioprine in kidney transplant recipients on steroid-free, low-dose cyclosporine immunosuppression (ATHENA): A pragmatic randomized trial. PLoS Medicine, 2021, 18, e1003668.	8.2	8
866	Preventing microalbuminuria with benazepril, valsartan, and benazeprilâ€“valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. PLoS Medicine, 2021, 18, e1003691.	8.2	8
867	Eicosanoids and Platelet Activating Factor as Possible Mediators of Injury in Experimental Nephropathies. Advances in Experimental Medicine and Biology, 1989, 259, 221-247.	9.0	8
868	Fluid Shear Stress Modulates von Willebrand Factor Release From Human Vascular Endothelium. Blood, 1997, 90, 1558-1564.	1.4	8
869	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home?. Clinical and Medical Investigations, 2020, 5, .	0.2	8
870	Challenges in Understanding Acute Postinfectious Glomerulonephritis: Are Anti-Factor B Autoantibodies the Answer?. Journal of the American Society of Nephrology: JASN, 2020, 31, 670-672.	0.5	8
871	International Society of Nephrologyâ€™s Perspective on the Emergence of Chronic Kidney Diseases of Unknown/Undetermined Etiology. MEDICC Review, 2014, 16, 75.	0.6	8
872	Nephrotic-range proteinuria in type 2 diabetes: Effects of empagliflozin on kidney disease progression and clinical outcomes. EClinicalMedicine, 2022, 43, 101240.	7.0	8
873	Low Nephron Number Induced by Maternal Protein Restriction Is Prevented by Nicotinamide Riboside Supplementation Depending on Sirtuin 3 Activation. Cells, 2022, 11, 3316.	4.2	8
874	Intermittent heparin treatment does not induce hypercoagulability in haemodialysed patients.. Journal of Clinical Pathology, 1980, 33, 631-634.	2.2	7
875	Platelet-activating factor alters glomerular barrier size selectivity for macromolecules in rats. American Journal of Physiology - Renal Physiology, 1991, 261, F85-F90.	2.8	7
876	Treatment of idiopathic membranous glomerulopathy. Current Opinion in Nephrology and Hypertension, 1994, 3, 155-163.	2.0	7
877	Recent developments in the management of membranous nephropathy. Expert Opinion on Investigational Drugs, 1997, 6, 521-532.	4.0	7
878	Are HUS and TTP genetically determined?. Kidney International, 1998, 53, 1085-1086.	5.3	7
879	Renoprotection: Clues from knockout models of rare diseases. Kidney International, 2003, 63, 764-766.	5.3	7
880	Autologous Stem Cell and Kidney Transplantation for Primary Amyloidosis Associated with ESRD: Which Should Come First?. American Journal of Transplantation, 2005, 5, 1585-1586.	4.7	7
881	Misleading meta-analysis: a need to look beyond the headlines. Diabetic Medicine, 2007, 24, 587-591.	2.5	7
882	Propionyl-L-carnitine prevents early graft dysfunction in allogeneic rat kidney transplantation. Kidney International, 2008, 74, 1420-1428.	5.3	7

#	Article	IF	Citations
883	Intensified inhibition of renin-angiotensin system: A way to improve renal protection?. Current Hypertension Reports, 2009, 11, 118-124.	3.3	7
884	Oral Acetyl- <scp>l</scp> -Carnitine Therapy and Insulin Resistance. Hypertension, 2010, 55, e26.	4.9	7
885	Thrombotic Microangiopathies, Including Hemolytic Uremic Syndrome. , 2010, , 344-355.		7
886	Hypertension after kidney transplantation. Journal of Hypertension, 2011, 29, 2310-2311.	0.5	7
887	Kidney Transplantation, Bioengineering, and Regeneration. , 2017, , xxv.		7
888	Epidemiology of End-Stage Renal Failure. , 2017, , 5-11.		7
889	Invited letter in response to: â€œIs the kidney donor profile index (KDPI) universal or UNOS-specific?â€. American Journal of Transplantation, 2018, 18, 1033-1034.	4.7	7
890	Mesenchymal Stromal Cells for AKI after Cardiac Surgery. Journal of the American Society of Nephrology: JASN, 2018, 29, 7-9.	0.5	7
891	Predictors of Net Acid Excretion in the Chronic Renal Insufficiency Cohort (CRIC) Study. American Journal of Kidney Diseases, 2019, 74, 203-212.	1.9	7
892	Xenotransplantation: A Step Closer to Clinical Reality?. Transplantation, 2019, 103, 453-454.	1.0	7
893	The impact of COVID-19 on total mortality in Italy up to November 2020. Panminerva Medica, 2021, , .	0.8	7
894	Ramipril and Cardiovascular Outcomes in Patients on Maintenance Hemodialysis. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 575-587.	4.3	7
895	Excess mortality in Italy in 2020 by sex and age groups accounting for demographic changes and temporal trends in mortality. Panminerva Medica, 2022, 64, .	0.8	7
896	IMMUNOMODULATION BY INTRATHYMIC INJECTION OF DONOR LEUKOCYTES IN RHESUS MONKEYS1. Transplantation, 2001, 72, 1432-1436.	1.0	7
897	Angiotensin-converting enzyme 2: from a vasoactive peptide to the gatekeeper of a global pandemic. Current Opinion in Nephrology and Hypertension, 2021, 30, 252-263.	2.0	7
898	Need for chronic kidney disease prevention programs in disadvantaged populations. Clinical Nephrology, 2015, 83 (2015), 42-48.	0.7	7
899	DOES ASPIRIN PRECIPITATE MAJOR GASTROINTESTINAL BLEEDING IN PATIENTS ON HÃ†MODIALYSIS?. Lancet, The, 1977, 310, 359-360.	11.9	6
900	Platelet and vascular prostaglandins in uraemia, thrombotic microangiopathy and pre-eclampsia. Philosophical Transactions of the Royal Society of London Series B, Biological Sciences, 1981, 294, 339-342.	2.2	6

#	Article	IF	Citations
901	Metabolism of thromboxane B2 in the isolated perfused rat kidney: mass spectrometric identification of urinary products. Lipids and Lipid Metabolism, 1989, 1006, 167-172.	2.3	6
902	Identification of a Novel Geneâ€"SSK1â€"in Human Endothelial Cells Exposed to Shear Stress. Biochemical and Biophysical Research Communications, 1998, 246, 881-887.	2.2	6
903	Tacrolimus and ciclosporin microemulsion in renal transplantation. Lancet, The, 2002, 360, 799-800.	11.9	6
904	Complement Factor H Gene Abnormalities in Haemolytic Uraemic Syndrome: From Point Mutations to Hybrid Gene. PLoS Medicine, 2006, 3, e432.	8.2	6
905	Does remission of renal disease associated with antihypertensive treatment exist?. Current Hypertension Reports, 2007, 9, 160-165.	3.3	6
906	Î²-cell transplantation for diabetes therapy â€“ Authors' reply. Lancet, The, 2008, 372, 29-30.	11.9	6
907	Novel therapies of lupus nephritis. Current Opinion in Nephrology and Hypertension, 2008, 17, 156-161.	2.0	6
908	Association ofCFHR1homozygous deletion with acute myelogenous leukemia in the European population. Leukemia and Lymphoma, 2016, 57, 1234-1237.	1.3	6
909	Longitudinal Assessment of the Effect of Atrasentan on Thoracic Bioimpedance in Diabetic Nephropathy: A Randomized, Double-Blind, Placebo-Controlled Trial. Drugs in R and D, 2017, 17, 441-448.	2.2	6
910	Reply to â€˜Strengths and limitations of estimated and measured GFRâ€™. Nature Reviews Nephrology, 2019, 15, 785-786.	9.3	6
911	Non-Shiga toxin-associated hemolytic uremic syndrome. , 2006, , 65-83.		6
912	A recurrent question from a primary care physician: How should I treat my COVID-19 patients at home? An update. Clinical and Medical Investigations, 2020, 5, .	0.2	6
913	Case Report: Tackling Complement Hyperactivation With Eculizumab in Atypical Hemolytic Uremic Syndrome Triggered by COVID-19. Frontiers in Pharmacology, 2022, 13, 842473.	3.6	6
914	Primary care in a National Health Service: time for radical reform. Family Practice, 2022, 39, 994-995.	2.1	6
915	Pathogenesis of Preeclampsia. , 1986, , 13-33.		5
916	Oral zeranol shortens the prolonged bleeding time of uremic rats. Kidney International, 1990, 38, 96-100.	5.3	5
917	Low-dose aspirin and bleeding in uremia. American Journal of Hematology, 1993, 42, 235-236.	4.2	5
918	Hemolytic uremic syndrome: Past and present. American Journal of Kidney Diseases, 2000, 36, liv-lvi.	1.9	5

#	Article	IF	Citations
919	Can We Really Lessen Kidney Damage to the Point that the Loss of Renal Function of Progressive Nephropathy May Revert?. Journal of the American Society of Nephrology: JASN, 2003, 14, 1411-1414.	0.5	5
920	Therapeutic use of HMG-CoA reductase inhibitors: current practice and future perspectives. Expert Opinion on Therapeutic Patents, 2004, 14, 1553-1566.	5.1	5
921	Kidney prevention recipes for your office practice. Kidney International, 2005, 67, S136-S141.	5.3	5
922	Inhibition of the renin-angiotensin system and cardio-renal protection: focus on losartan and angiotensin receptor blockade. Expert Opinion on Pharmacotherapy, 2005, 6, 1931-1942.	1.9	5
923	Let's assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?. Journal of Hepatology, 2006, 44, 837-838.	3.8	5
924	Complement hyperactivation may cause atypical haemolytic uraemic syndrome gain-of-function mutations in factor B. Nephrology Dialysis Transplantation, 2007, 22, 2452-2454.	0.7	5
925	Candesartan and renal protection: more than blocking angiotensin type 1 receptor?. Kidney International, 2008, 74, 1112-1114.	5.3	5
926	Islet transplantation: need for a time-out?. Nature Clinical Practice Nephrology, 2008, 4, 660-661.	0.9	5
927	Effect of Seliciclib (CYC202, R-Roscovitine) on Lymphocyte Alloreactivity and Acute Kidney Allograft Rejection in Rat. Transplantation, 2008, 85, 1476-1482.	1.0	5
928	Ethical disputes still beset Italian medicine 150 years after Count Cavour's death. Lancet, The, 2012, 379, 1068-1073.	11.9	5
929	Recent advances in immunosuppression and acquired immune tolerance in renal transplants. American Journal of Physiology - Renal Physiology, 2016, 310, F446-F453.	2.8	5
930	New biologics in the treatment of rare glomerular diseases of childhood. Current Opinion in Pharmacology, 2017, 33, 27-33.	3.5	5
931	Recellularization of Kidney Scaffold With Stem Cells. , 2017, , 877-886.		5
932	Data on the assessment of LV mechanics by speckle tracking echocardiography in ADPKD patients. Data in Brief, 2018, 21, 2075-2081.	1.1	5
933	Imaging the Kidney with an Unconventional Scanning Electron Microscopy Technique: Analysis of the Subpodocyte Space in Diabetic Mice. International Journal of Molecular Sciences, 2022, 23, 1699.	4.1	5
934	Sirtuins in kidney health and disease. Nature Reviews Nephrology, 2024, 20, 313-329.	9.3	5
935	ASPHYXIA IN GOODPASTURE'S SYNDROME: EARLY TREATMENT BY IMMUNOSUPPRESSION AND PLASMA EXCHANGE. Lancet, The, 1978, 311, 552.	11.9	4
936	STAGNATIONS AND REGRESSIONS IN THE TREATMENT OF PRIMARY GLOMERULONEPHRITIS. Lancet, The, 1983, 322, 90-92.	11.9	4

#	Article	IF	Citations
937	Effects of Tertatolol on Renal Function in the Isolated Perfused Rat Kidney. American Journal of Hypertension, 1989, 2, 223S-227S.	1.8	4
938	Induction of unresponsiveness via intrathymic inoculation. Lancet, The, 1991, 338, 450.	11.9	4
939	Turnour necrosis factor stimulates endothelin-1 gene expression in cultured bovine endothelial cells. Mediators of Inflammation, 1992, 1, 263-266.	3.0	4
940	Inflammation and glomerular injury. Seminars in Immunopathology, 1994, 16, 39-51.	4.0	4
941	The role of eicosanoids in the pathogenesis of hemolytic uremic syndrome. Prostaglandins Leukotrienes and Essential Fatty Acids, 1994, 51, 75-79.	2.3	4
942	Section Review Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis: New antirejection drugs. Expert Opinion on Therapeutic Patents, 1996, 6, 871-891.	5.1	4
943	Dearingâ€"a report to be embraced. Lancet, The, 1997, 350, 308.	11.9	4
944	Assessment of glomerular size-selective function with fractional clearance of neutral dextran. Translational Research, 1998, 132, 360-362.	2.3	4
945	Conflict of interest as seen from a researcherâ€™s perspective. Science and Engineering Ethics, 2002, 8, 337-342.	3.0	4
946	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	4
947	Role of thymic- and graft-dependent mechanisms in tolerance induction to rat kidney transplant by donor PBMC infusion. Kidney International, 2007, 71, 1132-1141.	5.3	4
948	KIDNEY FAILURE STABILIZES AFTER AN INCREASE OVER 2 DECADES. Journal of Renal Care, 2007, 33, 100-104.	1.2	4
949	Lymphocyte depletion for kidney transplantation: back to the past?. Nature Clinical Practice Nephrology, 2008, 4, 534-535.	0.9	4
950	Low Mortality and Key Aspects of Delivery of Care for End-Stage Renal Disease in Italy. Scientific World Journal, The, 2009, 9, 349-359.	2.2	4
951	Meta-analyses can misdirect decisions on treatment. Nature Reviews Nephrology, 2013, 9, 311-312.	9.3	4
952	Nephroprotection by dual RAS blockadeâ€"a welcome back. Nature Reviews Nephrology, 2015, 11, 507-508.	9.3	4
953	Comparison of exposure response relationship of atrasentan between <scp>N</scp>orth <scp>A</scp>merican and <scp>A</scp>sian populations. Diabetes, Obesity and Metabolism, 2017, 19, 545-552.	4.5	4
954	CRISPR-Cas9-Mediated Correction of the G189R-PAX2 Mutation in Induced Pluripotent Stem Cells from a Patient with Focal Segmental Glomerulosclerosis. CRISPR Journal, 2019, 2, 108-120.	2.9	4

#	Article	IF	Citations
955	Update on mesenchymal stromal cell studies in organ transplant recipients. Current Opinion in Organ Transplantation, 2020, 25, 27-34.	1.5	4
956	RIDE: Theia-Based Web IDE for the Reflex Language. , 2021, , .		4
957	Human iPSC-derived neural crest stem cells can produce EPO and induce erythropoiesis in anemic mice. Stem Cell Research, 2021, 55, 102476.	0.7	4
958	Genes and molecular medicine in the future of organ transplantation. Current Opinion in Organ Transplantation, 1999, 4, 65.	1.5	4
959	Unravelling the Role of PAX2 Mutation in Human Focal Segmental Glomerulosclerosis. Biomedicines, 2021, 9, 1808.	3.2	4
960	Hypoimmunogenic Human Pluripotent Stem Cells as a Powerful Tool for Liver Regenerative Medicine. International Journal of Molecular Sciences, 2023, 24, 11810.	4.1	4
961	Induction of unresponsiveness via intrathymic inoculation. Lancet, The, 1991, 337, 1487-1488.	11.9	3
962	Interleukin-6 stimulates gene expression of extracellular matrix components in bovine mesangial cells in culture. Mediators of Inflammation, 1993, 2, 429-433.	3.0	3
963	Innovative strategies for pharmacological intervention in immune damage to the kidney. Nephrology Dialysis Transplantation, 1995, 10, 1131-1136.	0.7	3
964	The Girl with the Curl. New England Journal of Medicine, 1995, 333, 928-931.	29.6	3
965	The scientific care for prevention: An overview. Kidney International, 2005, 67, S8-S13.	5.3	3
966	Mycophenolic Acid Formulation Affects Cyclosporine Pharmacokinetics in Stable Kidney Transplant Recipients. Therapeutic Drug Monitoring, 2006, 28, 643-649.	2.2	3
967	Treatment of Chronic Proteinuric Kidney Disease. Hypertension, 2009, 54, 29-31.	4.9	3
968	Omega-3 Polyunsaturated Fatty Acids Affect Sirolimus Exposure in Kidney Transplant Recipients on Calcineurin Inhibitor-Free Regimen. Transplantation, 2010, 89, 126-127.	1.0	3
969	Comment on: Robertson (2010) Islet Transplantation a Decade Later and Strategies for Filling a Half-Full Glass. Diabetes;59:1285-1291. Diabetes, 2010, 59, e13-e13.	0.9	3
970	Varying patterns of the antihypertensive and antialbuminuric response to higher doses of reninâ€“angiotensinâ€“aldosterone system blockade in albuminuric hypertensive type 2 diabetes mellitus patients. Journal of Hypertension, 2011, 29, 2031-2037.	0.5	3
971	Optimizing Allocation of Kidneys from Older Donors. American Journal of Transplantation, 2011, 11, 182-182.	4.7	3
972	Dual RAS blockadeâ€”controversy resolved. Nature Reviews Nephrology, 2013, 9, 640-640.	9.3	3

#	Article	IF	Citations
973	ISNâ€“ACCTS: global initiatives to improve clinical research. Nature Reviews Nephrology, 2014, 10, 426-427.	9.3	3
974	High serum cholesterol: a missed risk factor for chronic kidney disease mortality. Lancet Diabetes and Endocrinology,the, 2014, 2, 613-614.	11.1	3
975	Amnion epithelial cells are an effective source of factor H and prevent kidney complement deposition in factor H-deficient mice. Stem Cell Research and Therapy, 2021, 12, 332.	5.6	3
976	ADP, Ristocetin, Bovine Factor VIII and Thrombasthenic Platelets. Thrombosis and Haemostasis, 1976, 36, 286-288.	3.4	3
977	Kidney Disease. , 2017, , 235-252.		3
978	Shiga Toxin 2 Triggers C3a-Dependent Glomerular and Tubular Injury through Mitochondrial Dysfunction in Hemolytic Uremic Syndrome. Cells, 2022, 11, 1755.	4.2	3
979	MAFLD and glomerular hyperfiltration in subjects with prediabetes, visceral obesity and â€œpreservedâ€• kidney function: A cross-sectional study. Diabetes Research and Clinical Practice, 2023, 201, 110729.	2.8	3
980	Platelets from Uraemic Patients React Normally to Prostacyclin. International Journal of Artificial Organs, 1980, 3, 125-125.	1.4	2
981	Transplant tolerance: facts and future. Transplantation Proceedings, 1999, 31, 2955-2957.	0.6	2
982	Prostacyclin and Thromboxane and the Development of Preeclampsia. JAMA - Journal of the American Medical Association, 2000, 283, 1568.	6.9	2
983	Nitric oxide and renal perfusion in humans. Journal of Hypertension, 2002, 20, 391-393.	0.5	2
984	Angiotensin-converting enzyme inhibition or angiotensin receptor blockade in hypertensive diabetics?. Current Hypertension Reports, 2003, 5, 364-367.	3.3	2
985	Antihypertensive therapy in chronic renal disease. Journal of Hypertension, 2003, 21, 1625-1626.	0.5	2
986	Effect of a Novel Immunosuppressant, ST1959, on the Immune System and Renal Allograft Survival in Rats. Transplantation, 2005, 80, 231-236.	1.0	2
987	What blood-pressure level provides greatest renoprotection in patients with diabetic nephropathy and hypertension?. Nature Clinical Practice Nephrology, 2006, 2, 250-251.	0.9	2
988	Introduction to Focus on Fabry Nephropathy. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 359.	4.3	2
989	Stamina therapies: Time to call a halt. Nature, 2014, 506, 434-434.	35.3	2
990	The Lancet Kidney Campaign: an opportunity for partnerships. Lancet, The, 2016, 387, 1038-1039.	11.9	2

#	Article	IF	Citations
991	Italy, the Land of Holy Miraclesâ€"revisited. Lancet, The, 2016, 387, 11-12.	11.9	2
992	SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. Nephrology Dialysis Transplantation, 2018, 33, i317-i317.	0.7	2
993	A comparison of metrics and performance characteristics of different search strategies for article retrieval for a systematic review of the global epidemiology of kidney and urinary diseases. BMC Medical Research Methodology, 2018, 18, 110.	3.1	2
994	The Glomerulus: Mechanisms and Patterns of Injury. , 2018, , 189-206.		2
995	Functional Magnetic Resonance Imaging Versus Kidney Biopsy to Assess Response to Therapy in Nephrotic Syndrome: A Case Report. Kidney Medicine, 2020, 2, 804-809.	1.8	2
996	Case Report: Effects of Anti-SARS-CoV-2 Convalescent Antibodies Obtained With Double Filtration Plasmapheresis. Frontiers in Immunology, 2021, 12, 711915.	4.8	2
997	Insights into Glomerular Filtration and Albuminuria. New England Journal of Medicine, 2021, 385, 477-478.	29.6	2
998	Cyclosporine/tacrolimus (FK-506). , 1998, , 275-300.		2
999	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. Acta Diabetologica, 2022, 59, 309-317.	2.5	2
1000	The Glomerulus: Mechanisms and Patterns of Injuryâ˜†. , 2014, , .		2
1001	Proteinuria and Tubulotoxicity. , 2019, , 197-214.		2
1002	Therapeutic Small Interfering RNA Targeting Complement C3 in a Mouse Model of C3 Glomerulopathy. Journal of Immunology, 2022, 208, 1772-1781.	0.8	2
1003	Diffusion magnetic resonance imaging for kidney cyst volume quantification and non-cystic tissue characterisation in ADPKD. European Radiology, 0, , .	4.5	2
1004	Immunophenotypic Alterations in Adult Patients with Steroid-Dependent and Frequently Relapsing Nephrotic Syndrome. International Journal of Molecular Sciences, 2023, 24, 7687.	4.1	2
1005	A phase I study of autologous mesenchymal stromal cells for severe steroid-dependent nephrotic syndrome. Journal of Clinical Investigation, 2023, 8, .	6.5	2
1006	Endothelial Glycocalyx of Peritubular Capillaries in Experimental Diabetic Nephropathy: A Target of ACE Inhibitor-Induced Kidney Microvascular Protection. International Journal of Molecular Sciences, 2023, 24, 16543.	4.1	2
1007	A new era in the science and care of kidney diseases. Nature Reviews Nephrology, 2024, 20, 460-472.	9.3	2
1008	Aspirin and Thrombosis in Patients Undergoing Hemodialysis. New England Journal of Medicine, 1980, 302, 1420-1421.	29.6	1

#	Article	IF	Citations
1009	Are â€œRoutineâ€•Clinical and Laboratory Examinations of Any Help in the Treatment of Chronic Hemodialysis Patients?. American Journal of Kidney Diseases, 1987, 10, 23-27.	1.9	1
1010	Prostacyclin and Hemolytic Uremic Syndrome: From the Laboratory to An International Registry. International Journal of Artificial Organs, 1987, 10, 337-340.	1.4	1
1011	Analysis by fast atom bombardment mass spectrometry of phospholipids from tubuli, glomeruli, and urine of normal rats and rats with acute renal failure. Biochemical Medicine and Metabolic Biology, 1992, 48, 219-226.	0.7	1
1012	Defective glomerular [3H]lysoPAF metabolism in the autologous phase of rabbit nephrotoxic nephritis. Kidney International, 1993, 44, 747-754.	5.3	1
1013	Reducing mortality and increasing awareness. Lancet, The, 1998, 352, S20.	11.9	1
1014	Pharmacokinetics and renal function after conversion from standard to microemulsion formulation of cyclosporine in stable renal transplant patients. Transplantation Proceedings, 1998, 30, 1654-1655.	0.6	1
1015	Optimization of cyclosporine therapy in kidney transplantation. Transplantation Proceedings, 1998, 30, 1673-1676.	0.6	1
1016	Fluid loading: Neither safe nor efficacious in the treatment of the alcohol-intoxicated patient in the ED. American Journal of Emergency Medicine, 2000, 18, 121.	1.7	1
1017	Pharmacogenetics and pharmacogenomics of immunosuppressive agents: perspective for individualized therapy. Personalized Medicine, 2004, 1, 53-62.	1.3	1
1018	How should patients with, or at risk of, cardiovascular disease be screened for chronic kidney disease?. Nature Clinical Practice Nephrology, 2007, 3, 126-127.	0.9	1
1019	More on Renal Disease Progression: Is Interstitial Inflammation Truly Protective?. Journal of the American Society of Nephrology: JASN, 2007, 18, 1630-1632.	0.5	1
1020	Clinical perspectives in the prevention and treatment of chronic nephropathy, including an overview of the DEMAND Study. Clinical Therapeutics, 2007, 29, S64-S72.	2.2	1
1021	Role of Proteinuria in Progression. , 2008, , 2563-2576.		1
1022	New strategies to prevent cardiovascular risk in chronic kidney disease. Kidney International, 2008, 74, S1.	5.3	1
1023	Pathophysiology of Chronic Kidney Disease. , 2009, , 422-435.		1
1024	Medicine and art: one culture?. Kidney International, 2009, 75, 347-348.	5.3	1
1025	The deoxyuridine suppression test in HIVâ€1 positive patients: the role of azydothymidine (AZT). European Journal of Haematology, 1996, 56, 208-212.	2.2	1
1026	ERA-EDTA Immunonephrology working group. Nephrology Dialysis Transplantation, 2010, 25, 1706-1707.	0.7	1

#	Article	IF	Citations
1027	Exciting times for renal medicine. Lancet, The, 2010, 375, 1227-1228.	11.9	1
1028	Bone Marrow Mesenchymal Stem Cells in Organ Repair and Strategies to Optimize their Efficacy. , 2011, , 299-312.		1
1029	Initial combination therapy for treatment of hypertension. Lancet, The, 2011, 377, 1491.	11.9	1
1030	Role of Proteinuria in the Progression of Renal Disease. , 2013, , 2961-2983.		1
1031	Kidney Transplantation From a Donor With Acute Kidney Injury: An Unexpected Outcome. American Journal of Transplantation, 2014, 14, 977-978.	4.7	1
1032	Dreaming of normoglycaemia with fewer diet restrictions. Lancet Diabetes and Endocrinology,the, 2014, 2, 350-351.	11.1	1
1033	Interplay between Diagnostic Criteria and Prognostic Accuracy in Chronic Kidney Disease. PLoS Medicine, 2016, 13, e1002129.	8.2	1
1034	ISN Nexus 2016 Symposia: Translational Immunology in Kidney Diseaseâ€"The Berlin Roadmap. Kidney International Reports, 2016, 1, 327-339.	0.8	1
1035	Mesenchymal stromal cell-based therapy in kidney diseases and transplantation. Italian Journal of Medicine, 2019, 13, 3-14.	0.3	1
1036	Bleeding and Hemostasis in Acute Renal Failure. , 2019, , 630-635.e2.		1
1037	Protective Effects of Human Nonrenal and Renal Stromal Cells and Their Conditioned Media in a Rat Model of Chronic Kidney Disease. Cell Transplantation, 2020, 29, 096368972096546.	2.5	1
1038	SARS-CoV-2 Spike Protein 1 Activates Microvascular Endothelial Cells and Complement System Leading to Thrombus Formation. SSRN Electronic Journal, 0, , .	0.3	1
1039	Prevention of Chronic Renal Diseases in the Elderly. , 2008, , 231-255.		1
1040	The Onset and Resolution of Renal Fibrosis. , 2016, , 351-366.		1
1041	Nephropathy in NIDDM Patients, Predictors of Outcome. , 2000, , 237-246.		1
1042	Increased Fragmentation of von Willebrand Factor, Due to Abnormal Cleavage of the Subunit, Parallels Disease Activity in Recurrent Hemolytic Uremic Syndrome and Thrombotic Thrombocytopenic Purpura and Discloses Predisposition in Families. Blood, 1999, 94, 610-620.	1.4	1
1043	Two-hour post-dose cyclosporine monitoring does not fit all in kidney transplantation. Therapy: Open Access in Clinical Medicine, 2005, 2, 95-105.	0.2	1
1044	Defect Segmentation in Concrete Structures Combining Registered Infrared and Visible Images: A Comparative Experimental Study. Engineering Proceedings, 2021, 8, .	0.0	1

#	Article	IF	Citations
1045	Rationale and design of the CV-PREVITAL study: an Italian multiple cohort randomised controlled trial investigating innovative digital strategies in primary cardiovascular prevention. BMJ Open, 2023, 13, e072040.	2.1	1
1046	The ethics of peer review process. Updates in Surgery, 2023, 75, 1391-1392.	2.1	1
1047	Thyroid hormone treatment counteracts cellular phenotypical remodeling in diabetic organs. IScience, 2023, 26, 107826.	4.0	1
1048	Haemolytic Uraemic Syndromes. , 1984, , 276-297.		0
1049	Renal pathophysiology. Current Opinion in Nephrology and Hypertension, 1993, 2, 597-601.	2.0	0
1050	Haemolyticâ€"Uraemic Syndrome and Thrombotic Thrombocytopenic Purpura. Vascular Medicine Review, 1993, vmr-4, 273-292.	0.2	0
1051	Kidney/pancreas transplantation. Lancet, The, 1994, 343, 971-972.	11.9	0
1052	Renal pathophysiology. Current Opinion in Nephrology and Hypertension, 1994, 3, 431-435.	2.0	0
1053	Hemostasis in renal failure. Intensivmedizin Und Notfallmedizin, 1998, 35, 382-389.	0.1	0
1054	Double transplant of marginal kidneys. Transplantation Proceedings, 1999, 31, 2962-2964.	0.6	0
1055	The uses of error: diagnostic preferences. Lancet, The, 2001, 358, 1005.	11.9	0
1056	Corrigendum to â€œLetâ€™s assume that hepatitis C reduces the cardiovascular risk in dialysis patients: Are there practical implications?â€•[J Hepatol 44 (2006) 837â€“838]. Journal of Hepatology, 2006, 45, 339.	3.8	0
1057	Angiotensin-receptor blockers for renal protection in Type 2 diabetes. Aging Health, 2006, 2, 295-301.	0.3	0
1058	Is Mycophenolate Mofetil Better Than Azathioprine in Organ Transplantation?. Transplantation, 2006, 82, 1242-1243.	1.0	0
1059	A mouse model of non-Shiga toxin-associated haemolytic uraemic syndrome. Nephrology Dialysis Transplantation, 2007, 23, 462-465.	0.7	0
1060	Chapter 14 Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. Handbook of Systemic Autoimmune Diseases, 2007, , 257-282.	0.1	0
1061	Target haemoglobin concentrations in chronic kidney disease. Lancet, The, 2007, 369, 1515.	11.9	0
1062	Minimisation of immunosuppression in transplantation â€“ Authors' reply. Lancet, The, 2007, 370, 654.	11.9	0

#	Article	IF	Citations
1063	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2008, , 445-456.		0
1064	Rare but Relevant Kidney Disorders. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1701-1704.	4.3	0
1065	Effects of Combined Ezetimibe and Simvastatin Therapy as Compared With Simvastatin Alone in Patients With Type 2 Diabetes: A Prospective Randomized Double-Blind Clinical Trial. Diabetes Care, 2010, 33, e133-e133.	9.0	0
1066	The Glomerulus: Mechanisms of Injury*. , 2010, , 245-261.		0
1067	Staging CKD: can we rely on estimated GFRs?. Nature Reviews Nephrology, 2011, 7, 307-308.	9.3	0
1068	Cells for Treating Organ Damage: How Long Will We Need Them?. Journal of the American Society of Nephrology: JASN, 2011, 22, 590-592.	0.5	0
1069	Cavour's death and the political difficulties of Italian medicine â€“ Author's reply. Lancet, The, 2012, 380, 108-109.	11.9	0
1070	Prednisolone plus chlorambucil preserved renal function in membranous nephropathy. Annals of Internal Medicine, 2013, 158, JC9.	10.0	0
1071	Current Status of Islet Transplantation. , 2014, , 583-598.		0
1072	Nephrons are generated via a series of committed progenitors. Nature Reviews Nephrology, 2014, 10, 491-491.	9.3	0
1073	Pharmacotherapy options for membranous nephropathy. Expert Opinion on Orphan Drugs, 2016, 4, 185-196.	0.7	0
1074	Tissue Engineering of Renal Tissue (Kidney). , 2017, , 575-602.		0
1075	AAV9-mediated engineering of autotransplanted kidney of non-human primates. Gene Therapy, 2017, 24, 308-313.	4.6	0
1076	The Vaticanâ€“Mario Negriâ€“ Lancet Commission on the value of life. Lancet, The, 2017, 390, 1573.	11.9	0
1077	Addressing acute kidney injury in critically ill newborn babies. The Lancet Child and Adolescent Health, 2017, 1, 161-163.	5.4	0
1078	Developmental Approaches to Kidney Regeneration. , 2017, , 1039-1050.		0
1079	Prevention and Therapeutic Management of Bleeding in Dialysis Patients. , 2017, , 334-345.e1.		0
1080	Maintenance Immunosuppression in Kidney Transplantation. , 2017, , 259-276.		0

#	Article	IF	Citations
1081	Orphan drugs â€“ Authors' reply. Lancet, The, 2019, 393, 1595-1596.	11.9	0
1082	Why and how did Leonardo happen: the Renaissance context. Lancet, The, 2019, 393, 1396-1397.	11.9	0
1083	Functional outcome of displaced middle third clavicular fractures treated by plate osteosynthesis. International Journal of Research in Orthopaedics, 2021, 7, 335.	0.0	0
1084	COVID-19 from a pharmacological perspective. Advances in Biological Regulation, 2021, 81, 100821.	2.7	0
1085	Molecular Medicine in Organ Transplantation: How and When?. , 2001, , 317-334.		0
1086	Pharmacologic Monitoring of Immunosuppressive Drugs. , 2001, , 43-59.		0
1087	Platelets and renal diseases. , 2002, , 837-851.		0
1088	Mesenchymal Stem Cells and Their Use in Acute Renal Injury. , 2009, , 216-220.		0
1089	Bleeding and Hemostasis in Acute Renal Failure. , 2009, , 385-390.		0
1090	Acute Renal Failure in Kidney Transplant Recipients. , 2009, , 1660-1665.		0
1091	Hemolytic Uremic Syndrome/Thrombotic Thrombocytopenic Purpura. , 2010, , 349-364.		0
1092	Nondiabetic Kidney Disease. , 2010, , 341-356.		0
1093	Successes and Disappointments with Clinical Islet Transplantation. , 2013, , 1-27.		0
1094	Platelet and Vascular Prostaglandins in Uraemia, Thrombotic Microangiopathy and Pre-Eclampsia. , 1982, , 209-215.		0
1095	Prostanoid-Related Platelet Abnormalities in Renal Disease. , 1984, , 1406-1411.		0
1096	Eicosanoids and Acute Renal Failure. Current Concepts in Critical Care, 1990, , 115-129.	0.0	0
1097	Models of human renal disease. , 1990, , 111-123.		0
1098	Mechanisms and Mediators of Cyclosporine-Induced Renal Vascular Changes. , 1991, , 543-554.		0

#	Article	IF	Citations
1099	Altered Renovascular Endothelial Functions During Nephrotoxicity. , 1991, , 157-166.		0
1100	Aspirin in Hypertension of Pregnancy. , 1992, , 93-105.		0
1101	A Putative Role of NO and Oxidant Injury in the Pathogenesis of Hemolytic Uremic Syndrome. , 1997, , 418-427.		0
1102	Successes and Disappointments with Clinical Islet Transplantation. , 2015, , 1245-1274.		0
1103	Reply: Nephrons are generated via a series of committed progenitors. Nature Reviews Nephrology, 0, , .	9.3	0
1104	Commenti alla delibera. Mecosan, 2017, , 173-180.	0.2	0
1105	Acute Renal Failure in Kidney Transplant Recipients. , 2019, , 1279-1285.e3.		0
1106	Platelet and Vascular Prostaglandins in Uremia and Thrombotic Microangiopathy. , 1983, , 319-325.		0
1107	Platelet Prostaglandin Production in the Nephrotic Syndrome. , 1983, , 327-331.		0
1108	Thrombogenesis and Anticoagulation in Patients Undergoing Chronic Hemodialysis. , 1996, , 323-332.		0
1109	Interstitial Nephritis. , 2006, , 636-642.		0
1110	Diabetes Mellitus. , 2008, , 231-243.		0
1111	Lupus Nephritis. , 2008, , 244-252.		0
1112	Prostacyclin and Thromboxane and the Development of Preeclampsia. JAMA - Journal of the American Medical Association, 2000, 283, 1568-1569.	6.9	0
1113	DEVELOPING THERAPIES FOR C3G: REPORT OF THE KIDNEY HEALTH INITIATIVE C3G TRIAL ENDPOINTS WORK GROUP. Clinical Journal of the American Society of Nephrology: CJASN, 0, , .	4.3	0
1114	Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers for Advanced Chronic Kidney Disease. Annals of Internal Medicine, 0, , .	10.0	0
1115	GFR measurement in patients with CKD: Performance and feasibility of simplified iohexol plasma clearance techniques. PLoS ONE, 2024, 19, e0306935.	2.5	0